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Abstract 
Background 
Infection and malnutrition remain significant causes of under-five morbidity and mortality in sub-
Saharan Africa with a cyclical relationship between infection and malnutrition. Malnourished chil-
dren are more prone to infection and would benefit from vaccination which is the most cost-effec-
tive tool available against infectious disease. However due to nutrition-induced immune suppres-
sion the malnourished child may not respond as well to vaccination. 
Methods 
We explored the relationship between undernutrition and immune responses measured by anti-
body titres/IgG concentrations following one dose of yellow fever and measles vaccines in two 
cohorts of African children. Based on findings from our initial analysis we also assessed the lon-
gevity of responses to yellow fever vaccine in a third cohort of African children. World Health 
Organization z-scores for weight for age, weight for height and height for age were used to assess 
nutritional status. Vaccine responses to measles and yellow fever were measured by standard 
ELISA and sero/micro neutralization respectively. Linear and logistic regression models were built 
to assess the relationships between the covariates and vaccine responses. In addition, we ex-
plored correlation of a known immune modulator which is also a nutritional factor – iron on vaccine 
response. 
Results 
There was significantly higher seroconversion following yellow fever vaccination in Mali compared 
to Ghana (91.0 vs 63.5% (p <0.001), and a trend to better seroconversion at higher height for age 
scores. Females attained significantly higher post vaccination antibody concentrations than males 
(p<0.001) following measles vaccination. Five to six years post yellow fever vaccination within 
routine programmes one quarter of the children no longer had protective titers. Iron metabolism 
is down regulated in the first week of neonatal life. 
Conclusions 
Chronic malnutrition may negatively impact responses to yellow fever vaccines. Five to six years 
post routine vaccination over 25% of children were no longer protected (defined by antibody con-
centrations) from yellow fever suggesting vulnerability to disease. There may be scope for con-
sidering differing vaccines doses for boys and girls for measles vaccine. 
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1.1 Worldwide under five mortality 
In 2017 alone, an estimated 5.5 million children under the age of 5 years died around the 
world [1, 2]. This accounts for 15,000 children every day [1, 3]. While these deaths represent 
less than half the number of deaths in 1990 [1] these mortality figures remain unacceptably 
high, especially given that the mortality is mainly due to preventable causes [1]. Half of the 
deaths occurred in sub-Saharan Africa with a median under 5 mortality of 2.6 million [2] and 
an under five mortality rate of 76 deaths per 1000 live births in 2017 [2]. One in 13 children in 
this region do not reach their 5th birthday with wide regional differences in these figures[2]. 
 
 
Figure 1.1: Global distribution of under 5 mortality 
Source: United Nations Inter-Agency Group for Child Mortality Estimation (UN IGME) 2018 
 
1.1.1 Infection as a leading cause of under-five mortality 
The leading causes of under five deaths in 2017 were preterm birth complications, pneumonia, 
birth asphyxia, diarrhea and malaria [4]. Infectious disease thus remains a leading cause of death 
in children globally contributing to millions of the under five deaths [5-8]. The highest burden of 
infectious disease is also in sub-Saharan Africa with significant morbidity and mortality [5, 7]. 
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1.1.2 Vaccines as a tool to combat morbidity and mortality 
Vaccines are established as the most effective preventive intervention against infectious disease , 
[9-11] and it is estimated that vaccines have contributed to saving over 20 million lives and $350 
billion between 2001 and 2017 in 73 low and middle income countries [10]. It is documented that 
vaccines save 2- 3 million lives each year worldwide [12]. Vaccines have not only contributed to 
disease prevention and thus prevention of mortality, but in 1976 led to the eradication of smallpox 
[13-15]. With the current drive to eradicate polio largely driven by vaccination, prospects for erad-
ication are also in sight [16-18].  Rinderpest in animals has also been eradicated using vaccine 
interventions [19]. 
These extremely useful interventions however do not perform equally well in all settings and re-
actogenicity and immunogenicity have been reported to vary, depending on vaccine types and 
geographical regions [20-22]. Oral vaccines including oral polio vaccine and rotavirus vaccine are 
well documented to elicit poorer immune responses in resource poor settings [23, 24]. Un-
published data from my previous work also revealed that the reactogenicity to the 13-valent pneu-
mococcal conjugate vaccine varied widely from region to region even where identical delivery 
mechanisms were utilized. Studies exploring some of the factors that mediate these differences 
in vaccine responses from region to region may contribute data that ensures optimal use of avail-
able interventions and provide a basis for modifying interventions to suit populations or modifying 
the host to enhance response to the intervention. This may include the need to modify vaccination 
schedules, provide supplements along with immunization programmes or modify environmental 
conditions in a drive to derive the best strategies for individuals and populations alike. 
1.2 Malnutrition and infection and immunity 
In addition to infectious diseases, malnutrition contributes significantly to nearly half of the annual 
deaths in the under-five age group [1, 25]. In 2017, nutrition related factors contributed to 45% of 
the deaths in children under 5 years of age [4, 26]. Closely linked to the morbidity and mortality 
due to malnutrition is the greater susceptibility of malnourished children to infection.  Malnourished 
children have the highest risk of death from preventable infectious diseases such as measles, 
diarrhoea, malaria and pneumonia, especially in the context of acute undernutrition [3, 25, 27, 28]. 




Figure 1.2: Conceptual framework on the relationship between malnutrition, infections and poverty.  
Source: Rytter MJH et al. doi:10.1371/journal.pone.0105017.g001  
 
1.2.1 Malnutrition and vaccine responses 
As vaccines are proven to be a cost-effective intervention against infectious disease morbidity 
and mortality in general, vaccinating malnourished children is likely to be of particularly high ben-
efit given the unique predisposition of these children to infectious disease. However, the vaccines 
might not work equally well in the malnourished for the same reason they are predisposed to 
infection – malnutrition-associated immune suppression [27]. The impaired ability to overcome 
infectious diseases is thought to be due in part to deficiencies in the innate, and adaptive arms of 
immunity documented in these children [30]. Undernutrition is also associated with impaired gut 
barrier function, implicated in the poorer responses to oral vaccines [23, 31]. Also documented is 
reduction in exocrine secretion of protective substances and decreased concentrations of plasma 
complement [31]. The thymus and other lymphatic tissue undergo atrophy and delayed type hy-
persensitivity reactions are less pronounced [31]. 
These factors might therefore affect not only responses to infection but also to vaccination. Vac-
cination guidelines for immunosuppressed children with advanced human immunodeficiency vi-
rus (HIV) infection and primary immune deficiencies recommend the avoidance of live vaccines 
which can cause severe or fatal reactions due to uncontrolled replication of the vaccine virus or 
bacterium [32, 33]. In addition, the local and regional reactions which follow Bacille Calmette 
Guerin (BCG) vaccination are enhanced in the immune suppressed [34, 35]. A mouse model also 
confirms these findings:  higher proportions of undernourished mice exhibited bacterial dissemi-
nation to lymph nodes following vaccination with BCG [36]. 
Current guidelines for management of malnutrition do not include recommendations for adapta-
tion of vaccines or schedules, and children with malnutrition are generally vaccinated according 
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to the same routine schedule as well-nourished children, except in the presence of severe acute 
illness [37]. The immune responses and reactogenicity (local and systemic reactions) to vaccines 
elicited in malnourished children compared to well-nourished children remains a poorly re-
searched area, and more data are required to inform the question as to whether vaccination ought 
to be adapted in the context of malnutrition, given that it remains a leading cause of preventable 
childhood deaths globally. If vaccines do not perform equally well in the context of malnutrition, 
practices might require adaptation in children with malnutrition. 
The period of growth faltering coincides with the delivery of routine vaccines within the Expanded 
Programme on Immunization (EPI), including yellow fever, measles and oral polio vaccines [37]. 
It already occurs around the period of introducing complementary feeds starting at 3 to 6 months 
of age in much of sub-Saharan Africa and is noticed in up to 50% of children attending infant 
welfare clinics [38-40]. This faltering persists well into the 5th year [38]. It is therefore particularly 
important to assess the vaccine responses in the context of nutrition in the second half of infancy 
(6-12 months), where important live vaccines are used. In many countries which fall into the Afri-
can meningitis belt, the MenAfriVac vaccine a serogroup A conjugate meningococcal vaccine has 
also been introduced for this age group[41]. 
In clinical practice malnutrition is often measured using the World Health Organization (WHO) z-
scores for weight for age, height for age and weight for height. These standards have evolved 
over the years and were developed using data collected in the WHO Multicentre Growth Refer-
ence Study. These guidelines were first published in 2006 based on data from 1990 collected 
from British children. The 2006 standards were based on breastfed infants from different ethnic 
groups. These standards define varying degrees of malnutrition as standard deviations from 
median values [42]. 
Factors such as age, [43-45] sex, [46, 47] geographical location, [45, 48, 49] seasonality [50] and 
pre-existing immunity [51] may all have additional impact on vaccine-induced protection. These 
factors therefore ought to be considered as covariates when assessing vaccine responses. 
In the current era of precision medicine and precision vaccinology with a drive to tailor interven-
tions to specific populations rather than have generic ‘one size fits all’ interventions, it is important 
to explore these questions to guide the use of available interventions or production of newer in-
terventions. 
1.3 Yellow fever 
Yellow fever is among the most feared and disruptive epidemic-prone diseases. Endemic in 
sub-Saharan Africa and the Americas, yellow fever is caused by a flavivirus transmitted through 
the bite of infected Aedes aegypti mosquitoes [52]. The intermediate host is the rhesus monkey. 
[53] The incidence of this potentially severe haemorrhagic disease has markedly reduced since 
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the introduction of vaccines against the virus. There have however been several recent out-
breaks in some cases beyond the tradition regions known for these outbreaks [52, 54]. The vast 
majority - ninety five percent of the remaining cases occur in Africa [55]. 
Effective vaccines against yellow fever virus have been available for routine use in yellow fever 
endemic regions of Africa and Asia since the year 1937 [53]. All currently available yellow fever 
vaccines are live attenuated vaccines, which are known to be highly immunogenic with a single 
dose generally providing long term protection [53]. The primary correlate of protection is neutral-
izing antibody, though cell mediated and innate immune responses have also been proposed to 
play a role in protection [56]. It may however be that protection is not universally consistent 
across different geographical settings and age groups.  A study in Brazilian infants reported var-
ying seroconversion rates in children of different ages [44]. Previous analysis of data from the 
MenAfriVac trials also noted varying seroconversion rates between countries [57]. Seroconver-
sion rates of 93% immediately following vaccination have been reported from adults in Brazil, 
but lower rates of 87 % for yellow fever vaccine given alone and 70% when given with Measles, 
Mumps Rubella (MMR) vaccine were reported in Brazilian children in the immediate post vac-
cination period [45, 48]. In contrast to this, a previous study from the Gambia conducted in well-
nourished children as part of a trial of the immunogenicity and safety of inactivated polio vaccine 
(IPV) reported seroconversion rates for yellow fever of 95% and above when given alone or in 
conjunction with varying combinations of Measles, MMR vaccines and IPV [49]. 
The current World Health Organization (WHO) guidance for the use of yellow fever vaccines 
recommends a single dose of yellow fever vaccine for life and fractional doses in outbreak situa-
tions where vaccine availability is limited. This is in contrast to previous recommendation of re-
peated doses every ten years [58-61]. A number of research priorities have been identified by 
WHO to ensure continued optimal use of this otherwise highly effective vaccine, including the 
conduct of further studies to identify at risk groups who may require a booster dose, to include 
infants and immunocompromised individuals such as those with HIV infection; and examination 
of vaccine responses where yellow fever vaccines have been administered concomitantly with 
other live vaccines, in particular the MMR vaccine [58]. 
Whether immunogenicity of yellow fever vaccine could also be affected by malnutrition- has not 
been systematically investigated to date. The yellow fever vaccine is given routinely at 9 months 
in most of the developing world - an age when growth faltering and malnutrition are common 
problem [28, 30]. New threats from yellow fever including outbreaks have recently emerged 
[54]. This includes, the risk of urban yellow fever infection due to transmission of the virus by the 
vector, increasing in Africa, and the potential for urban YF returning to South America. Both pre-
sent serious potential public health problems especially in settings with large population density 
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[55]. Geographical areas affected by yellow fever have also recently expanded to include areas 
previously considered risk free [62]. 
The recent changes to vaccination recommendations for yellow fever at a time of changing 
threats, calls for further assessments of potential impact of these important and prevalent co- 
factors in order to continue optimal use of this otherwise highly protective vaccine. 
1.4 Measles 
 
Measles is a highly contagious systemic viral disease still responsible for significant mortality 
and morbidity and has the potential to lead to major epidemics [63, 64]. The illness is caused by 
a negative-sense RNA virus with a non-segmented genome and a lipid envelope of the genus 
morbillivirus and the family Paramyxoviridae. The most recent concerns around measles include 
outbreaks in several countries during 2019 and still ongoing in June 2019 having first being 
noted in late 2018 [65-67]. Over 60,000 individuals have been infected in 3 countries (Ukraine, 
Philippines and Brazil) alone with 340 deaths as at 19th March 2019 [65, 66]. The first four 
months of 2019 saw a 700% increase in measles cases reported from the WHO Afro region 
compared to the same period in 2018 [67]. Outbreaks have occurred in all WHO regions [66] 
and the containment of measles has gained high prominence in public health institutions across 
high and low income countries alike in recent months [66, 68]. 
Live attenuated vaccines are available against measles and these vaccines are safe and immu-
nogenic and provide long lasting protection [63, 69]. Two doses are recommended to suscepti-
ble children and adults either as measles alone or concomitantly with other antigens such as 
mumps and rubella as combination or single antigen vaccines and with varicella vaccine [37]. 
Reaching all children with 2 doses of measles containing vaccine should be routine for all coun-
try’s immunization programmes with elimination possible at coverage rates over 95% [37]. In the 
most recent outbreaks over half of the cases which occurred in most countries were in unvac-
cinated individuals or those with unknown vaccination status [65, 70]. 
In much of the developing world, measles vaccine is administered at 9 months of age with a 
booster dose given at the age of 15 month in some countries [37]. The immune response to 
measles vaccine is age dependent, partially inhibited by maternal antibody (Ab) and involves 
induction of both Ab and T cell responses [63]. Neutralizing antibodies are considered a corre-
late of protection [63, 71]. 
Measles vaccine antibody responses have previously been shown to be affected by anthropo-
metric parameters [72]. This study described weight for height/length as impacting antibody 
concentrations 1-year post vaccination. Of the children with normal weight for height/length, 
75% had serum IgG concentrations above the defined threshold for protection compared to 
59% of those with reduced weight for height/length [72]. It is not clear what cut off z score was 
used for this study however, and other measures of under nutrition were not assessed.  
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WHO’s 2017 position paper on measles vaccines calls for research targeted at programmatic 
issues for delivery of measles containing vaccines and for special groups to target with vaccina-
tion. 
2 Rationale and Objectives 
We hypothesize that due to possibly subtle underlying immune suppression in malnourished 
children, routine vaccines given to this group of children will be less immunogenic compared to 
their well-nourished counterparts. Such poor responses may lead to inferior disease protection 
particularly in terms of quality and longevity of vaccine response, leaving an already vulnerable 
group of children more vulnerable to preventable infectious disease.  
We chose to investigate the relationship between yellow fever and measles vaccines antibody 
responses and anthropometric parameters in children nine to 11 months of age, an age well 
documented to be particularly associated with malnutrition and growth faltering in the develop-
ing world, [28, 30] and an age where important live vaccines are routinely given. We had access 
to a data from several large clinical studies conducted among children in sub-Saharan Africa. 
We examined differences in seroconversion rates and quantitative titres to yellow fever and 
measles by age, sex and country, and we assessed the effect of season of vaccination and pre-
existing antibody titres in a set of data available to us from these studies, as outlined below. 
 
2.1 Primary objective: 
To explore differences in immune responses to vaccination in well-nourished infants and infants 
with under- nutrition 
2.2 Secondary objectives: 
1. To assess differences in immune responses based on degree of under nutrition. 
2. To assess the longevity of vaccine responses. 
3 Methods and Materials 
To address the question of a potential link between anthropometric and co factors to immune 
responses to yellow fever and measles vaccination, we analysed available data from three of 
the large-scale vaccine trials that led to licensure of a new vaccine against meningococcal A 
meningitis (MenAfriVac/PsA-TT) and in which our research organisation was a collaborator. I 
was a co-investigator for 3 of these studies. 
The Meningitis Vaccine Project (MVP), a partnership between the World Health Organization 
(WHO) and the Program for Appropriate Technology in Health (PATH) conducted these studies 
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in the African meningitis belt which extends from Ethiopia to Senegal through a public-private 
partnership with the Serum Institute of India.[41, 73].  
 
3.1 Materials 
In order to achieve licensure of the MenAfriVac (PsA-TT) vaccine, 9 studies were conducted in 
individuals 14 weeks to 35 years within the African meningitis belt. Participants were vaccinated 
with MenAfriVac and followed up for up to 5 years between 2005 and 2012. These studies thus 
resulted in collection of a wide range of clinical and laboratory data and samples. This data and 
serum is available under a memorandum of understanding between PATH and Serum Institute 
of India to be accessed by investigators wishing to conduct relevant analysis with the available 
data and samples. 
To carry out this analysis I accessed data and serum samples as available from the studies that 
included children within the targeted age group of 9 to 11 months at the time of receiving a vac-
cination. This age group was targeted as it represents a period when routine vaccines are given 
after the onset of documented growth faltering. Data and serum from 3 studies across 3 coun-
tries has been utilized. The original studies are described in brief below: 
 
3.1.1 Original study designs 
Study PsA-TT 004 conducted in Navrongo, Ghana: 
Between November 2008 and August 2009, 1,200 participants were enrolled at 14-18 weeks of 
age and depending on the group to which the participant was randomized, first dose of the 
study vaccine was received at 14 weeks, 9 months, or 12 months of age. Children received one 
or two doses of different dosages of MenAfriVac. The control group was vaccinated with MenAf-
riVac at the end of study but there was no post-vaccination blood draw. 
For the purposes of my analysis only data from infants who received, measles, yellow fever and 
MenAfriVac vaccines at age 9 to 11 months at standard concentration was utilized. Data from 
the pre-vaccination and 28 days post vaccination time point were accessed for yellow fever vac-
cine responses. 
 
Study PsA-TT 007 conducted in Bamako, Mali: 
Between March 2012 and December 2012, participants were enrolled and randomized to re-
ceive one or two doses of different dosages of MenAfriVac. All children were enrolled at 9-12 
months of age. For the purposes of my analysis only data from infants who received, measles, 
yellow fever and MenAfriVac vaccines at standard concentration was utilized. Data from the 
pre-vaccination and 28-day post vaccination time point were accessed for both yellow fever and 
16 
measles vaccine responses. For responses to measles vaccine, data was also available for IgG 
responses to measles 6 months post vaccination. 
 
Study PsA-TT 002 conducted in Basse, The Gambia and Bamako, Mali: 
Between September and November 2006, six hundred and one (601) twelve to twenty-three-
month-old toddlers were recruited in The Gambia and Mali. The infant received in a 1:1:1 ratio a 
dose of either MenAfriVac, the licenced polysaccharide tetravalent vaccine containing 
serogroup A, C, W and Y strains (PsACWY) or Haemophilus influenza type b vaccine conju-
gated to tetanus toxoid (Hib-TT). A second vaccine dose was given 6 months later again ran-
domized in a 1:1:1 fashion creating a total of 9 groups. For the purposes of my analysis, data 
from an extended time point 4 to 5 years post the original study was assessed for yellow fever 
vaccine responses (see below). All infants enrolled had completed the primary series of EPI 
vaccines according to local schedule prior to enrolment. Blood samples were collected prior to 
vaccination in the study, 4 weeks post vaccination, prior to secondary vaccination, and approxi-
mately 1, 2- and 5-years post vaccination. The 5-year time point was the Pers-002 study (see 
below). 
 
Study Pers-002-003 conducted in Basse, The Gambia and Bamako, Mali: 
Participants who participated in 2 studies PsA-TT-002 and 003 and were enrolled between Oc-
tober 2011 and April 2012 to have a single blood draw to measure immune persistence since 
their last study visit (up to 4-5 years after first vaccination). 
For the purposes of my analysis, data from the Pers-002 study were accessed as these children 
had originally been enrolled at age 12 – 23 months shortly after routine yellow fever vaccination 
– N= 481. An enrollment criterion for the original PsA-TT 002 study, for which this study was a 
follow up, was the requirement to have received all required EPI vaccines as dictated by the lo-
cal schedules. For both countries this included concomitant measles, yellow fever and OPV 
vaccines at the age of approximately 9 months of age.  
The serum from these individuals will also be utilized to assay iron and vitamin D at the point 
just prior to vaccination in the initial studies at 12 - 23 months of age. These nutritional markers 
will then be correlated to vaccine responses for my post-doctoral research. 
For the MenAfriVac persistence study, a single serum sample was collected from the original 
participants between November 2011 and January 2012, approximately 5 to 6 years post re-
ceipt of yellow fever vaccine within routine EPI programmes. 
For my analysis, serum from these participants was utilized to assay IgG antibody to yellow fe-
ver as a follow up to findings from the yellow fever IgG concentrations noted in the Malian and 
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Ghanaian cohorts. Of note, there were no baseline titres or anthropometry at the time of vac-
cination for comparison. 
 
3.2 Data/Sera Retrieval Process: 
Prior to receiving the data and samples, I completed data/sera access forms and sought the 
written consent from the original investigators of these studies to access the data. These forms 
were then reviewed by a team at the Program for Appropriate Technology in Health and the Se-
rum Institute of India. After obtaining these permissions, I applied for and received ethical ap-
provals from the local ethics committees in all the countries where the data and samples had 
been collected to use the available data/samples for this purpose. This was followed by secure 
transmittal of the data to me and sample shipments from the sera bank Laboratorio di Epidemio-
logia Molecolare facility affiliated to the Dipartimento di Fisiopatologia, Medicina Sperimentale 
Sanità Pubblica of the University of Siena in Italy (UNISI) where all the serum samples were 
held. 
 
3.3 Nutritional assessments: 
Nutritional parameters for both groups were defined using the World Health Organization 
(WHO) z-scores for weight for age, height for age and weight for height just prior to vaccina-
tion.[42]. These standards were published in 2006, based on breastfed infants and appropriately 
fed children raised in optimal conditions and from different ethnic groups. These standards de-
fine varying degrees of malnutrition as standard deviations from median values. [42] 
 
3.4 Nutrition and antibody response to yellow fever vaccine 
We investigated the relationship between yellow fever and measles vaccine antibody responses 
and anthropometric parameters in children nine to 11 months of age. We examined differences 
in seroconversion rates and quantitative titres by age, sex and country, and we assessed the 
effect of season of vaccination and pre-existing antibody titres 
3.4.1 Participants 
Details of the trials are provided above. In summary, participants for the comparison of vaccine 
responses to anthropometry, were originally enrolled into two trials conducted across the Afri-
can meningitis belt to test the safety, immunogenicity, dose response and schedule of MenAfri-
Vac. This vaccine has recently been introduced across the African meningitis belt in a bid to 
eliminate periodic meningococcal A epidemics. The trials were conducted between 2008 and 
2013. The trial in urban Mali recruited 1,500 infants aged 9-18 months between March 2012 and 
18 
September 2013, while the study in rural Ghana recruited 1,200 infants aged 14 -18 weeks be-
tween Nov 2008 and May 2012 [41, 73]. 
For this analysis, we included data from all 393 participants who had received yellow fever vac-
cine at 9 to 11 months of age from clinical trial teams and had results available for yellow fever 
antibody titres at 2 time points pre and post vaccination.[74, 75] Serum samples were collected 
pre- and 28 days post vaccination.  
All infants had received a single dose of yellow fever vaccine (see below) from the trial teams. 
In addition, they all received a single dose of measles (Serum institute of India) and Oral Polio 
Vaccine (GlaxoSmithKline) together with MenAfriVacTM (Serum Institute of India). 
Both yellow fever vaccines were live attenuated freeze-dried vaccines containing ³ 1000 lethal 
dose 50 units per dose. The FioCruz yellow fever 17D strain sub strain 17DD vaccine (used in 
Ghana) has an antigen concentration of between 4·34 log10 plaque-forming units (PFU) and 
4·56 log10 PFU per dose. The Federal State Unitary Enterprise of Chimakov Institute of Poliomy-
elitis and Viral Encephalitis Russian Academy of Med Sciences 17D strain (used in Mali) has a 
vaccine concentration between 4·5 log10 plaque-forming units (PFU) and 4·7 log10 PFU per 
dose. 
3.4.2 Laboratory methods:  
All yellow fever vaccine responses had originally been measured using a neutralization assay 
optimised and available at the Robert Koch-Institute (RKI) in Berlin. The assay was done using 
the yellow fever -17D target virus strain in a concentration of 100 tissue culture infectious dis-
ease dose, 50% (TCID50) per well produced at RKI. Dilutions yielding ³ 50% neutralization after 
5 days were expressed as neutralization titres based on the dilution which attained this [57].  To 
mitigate against batch effects from different runs of the samples, a human serum sample with a 
medium neutralization titre was run as an internal control for each batch of samples run. If this 
control did not react as a medium titre the batch of samples was rerun. The threshold of 1:5 was 
considered as protective antibody titres while seroconversion was defined as at least a four-fold 
increase in antibody titre [71, 76]. Titres were measured as a ratio. All yellow fever assays were 
carried out in the same laboratory, using identical procedures. 
3.4.3 Statistical methods: 
Where applicable, antibody titres were normalized by log 2 transformation. Uni and multivariable 
mixed effects models were applied with random effects for country, adjusting for age, sex, sea-
son of vaccination and pre-vaccination titres as fixed effects. Separate models were run for se-
roconversion (binary outcome), raw post-vaccination antibody titres (continuous) and protection 
post-vaccination (binary) using logistic regression for binary outcomes and linear regression for 
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continuous outcomes. Means, medians, proportions and odds ratios were calculated along with 
their corresponding 95% confidence intervals. An alpha error level of 5% was used to judge sig-
nificance. Where applicable data were log transformed to normalize them. Data analysis was 
done using Stata version 14.2 [77]. 
 
3.5 Nutrition and response to measles vaccine 
3.5.1 Participants: 
For measles vaccine responses, data from 1,105 children was analysed at baseline and 28 
days post vaccination. Data was also available from 1,081 of these children 6 months post vac-
cination and was examined at this time point. These infants were all from Mali.  
Data from infants who had received measles and yellow fever vaccines concomitantly at 9 to 11 
months of age was reanalysed to correlate nutritional status at the time of vaccination to subse-
quent response to these vaccines.   
The infants had originally participated in a randomised controlled clinical trial conducted in Mali, 
to test the safety, immunogenicity and dosing schedule for the MenAfriVac vaccine. All infants 
had received measles and yellow fever vaccines from the trial teams during their participation in 
the trial at 9 – 11 months of age. All responses presented follow 1 dose of the vaccine in ques-
tion. No booster doses had been given.  
Infants the study received measles vaccine produced by Serum Institute of India Limited. 
3.5.2 Lab methods:  
Measles responses were measured by measles specific IgG concentration using a standard 
measles specific IgG ELISA kit IGG Virion Serion at UNISI. Batch effects (day to day variations 
and deviations) were minimized by running a test sample with each batch of samples run. In ad-
dition, multiplication of the current measured value obtained with a sample with a correction fac-
tor F was done. This procedure served to adjust the current test level of the user with a lot-spe-
cific standard curve. Values which fell below the lower limit of detection were assigned a value 
of 50mIU/mL.  
F = OD of reference value (of standard serum) 
      OD of current value (of standard serum) 
OD = optical density 
 A threshold of 120mIU/ml was considered as the cut off for protection [71, 78-80]. This is de-
fined as a definite correlate of protection given that the presence of this antibody concentration 
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is almost always associated with protection from disease. [71] Seroconversion was defined as 
at least a 4-fold rise in antibody concentration from baseline [71, 79].  
 
3.5.3 Statistical methods: 
Statistical methods similar to those for responses to yellow fever were used. However, since all 
children belonged to the same cohort, there was no need to use mixed effects models as in the 
yellow fever analyses. In addition, attempts to perform multivariable regression analysis of z 
scores as predictor variables of the binary threshold of protection outcome adjusting for age and 
sex resulted in null cells, thus only pre-vaccination titres and season of vaccination was ad-
justed for, when this parameter was considered. 
 
4. Results 
4.1 Nutrition and antibody response to yellow fever vaccine  
Pre- and post-vaccination data from a total of 393 children were utilized to explore the relation-
ship between anthropometry and antibodies to yellow fever.  
The mean age in this cohort was 9.22 (95%CI = 9.17 – 9.28) months. The mean antibody titres 
pre-and post-vaccination were 3.12 (2.96 - 3.27) and 35.48 (31.23 – 39.72) respectively. The 
mean fold change post vaccination was a 12.93 (11.18 – 14.68) fold rise in antibody titre. Other 
cohort characteristics are detailed in Table 4.1. 
 
Table 4.1: Cohort characteristics – yellow fever antibody responses. 
N = 393 All Male (54%) Female (46%) 
Country 
Both  
N = 393 
Variable Mean (95% CI) Median (IQR) Mean (95% CI) Median (IQR) Mean (95% CI) Median (IQR) 
 Age (months) 9·22 (9·17, 9·28) 9·00 (9·00, 9·00) 9·26 (9·18, 9·34) 9·00 (9·00, 9·00) 9·21 (9·13, 9·29) 9·00 (9·00, 9·00) 
 Weight (kg) 8·19 (8·09, 8·28) 8·10 (7·50, 8·80) 8·35 (8·22, 8·47) 8·30 (7·80, 8·90) 8·00 (7·86, 8·14) 8·00 (7·30, 8·70) 
 Height (cm) 70·9 (70·7, 71·1) 71·0 (69·1, 72·0) 71·2 (70·9, 71·6) 71·0 (70·0, 73·0) 70·5 (70·2, 70·9) 70·2 (69·0, 72·0) 
 Weight for age 
z-score 
-0·54 (-0·64, -0·44) -0·72 (-1·42, 0·00) -0·71 (-0·84, -0·57) -0·75 (-1·32, -0·01) -0·35 (-0·49, -0·20) -0·33 (-0·99, 0·27) 
 Height for age 
z-scores 
-0·24 (-0·34, -0·13) -0·23 (-0·88, 0·38) -0·47 (-0·61, -0·34) -0·43 (-1·15, 0·01) 0·05 (-0·11, 0·20) -0·06 (-0·60, 0·77) 
 Weight for 
height z-score 
-0·71 (-0·83, -0·60) -0·61 (-1·21, 0·08) -0·78 (-0·95, -0·62) -0·79 (-1·50, -0·03) -0·63 (-0·79, -0·47) -0·69 (-1·30, 0·12) 
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 YF Ab (base-
line) = a 
3·12 (2·96, 3·27) 2·00 (2·00, 4·00) 3·11 (2·89, 3·33) 2·00 (2·00, 4·00) 3·12 (2·90, 3·34) 2·00 (2·00, 4·00) 
 YF Ab (28 
days post vac) 
= b 
35·48 (31·23, 39·72) 22·00 (11·00, 45·00) 38·74 (31·76, 45·71) 32·00 (11·00, 45·00) 31·61 (27·38, 35·85) 22·00 (11·00, 45·00) 
 YF Ab fold 
change a to b 
13-fold (11, 15) 8-fold (4,16) 14-fold (11, 17) 11-fold (4, 16) 11-fold (10, 13) 8-fold (4, 16) 
Mali  




Male – 56%  Female – 44%  
 Age (months) 9·34 (9·25, 9·42) 9·00 (9·00, 9·00) 9·36 (9·24, 9·47) 9·00 (9·00, 9·00) 9·32 (9·19, 9·45) 9·00 (9·00, 9·00) 
 Weight (kg) 8·31 (8·20, 8·42) 8·15 (7·80, 8·80) 8·45 (8·31, 8·58) 8·40 (7·90, 8·90) 8·13 (7·97, 8·30) 8·00 (7·50, 8·70) 
 Height (cm) 71·1 (70·7, 71·4) 71·0 (70·0, 73·0) 71·3 (70·9, 71·7) 71·0 (70·0, 73·0) 70·7 (70·3, 71·3) 71·0 (69·5, 72·0) 
 Weight for age 
z-score -0·43 (0·86, -0·52) -0·52 (-1·02, 0·09) -0·61 (-0·76, -0·46) -0·67 (-1·09, -0·11) -0·21 (-0·38, -0·05) -0·23 (-0·80, 0·41) 
 Height for age 
z-scores -0·25 (1.02, -0·12) -0·12 (-0·88, 0·35) -0·51 (-0·67, -0·35) -0·43 (-1·32, 0·01) 0·10 (-0·10, 0·30) 0·09 (-0·54, 0·77) 
 Weight for 
height z-score -0·56 (1.01, -0.59) -0·59 (-1·20, 0·00) -0·63 (-0·81, -0·45) -0·59 (-1·18, -0·14) -0·49 (-0·68, -0·30) -0·57 (-1·21, 0·12) 
 YF Ab (base-
line) = a 3·35 (3·15, 3·56) 4·00 (2·00, 4·00) 3·32 (3·06, 3·57) 4·00 (2·00, 4·00) 3·40 (3·07, 3·73) 4·00 (2·00, 4·00) 
 YF Ab (28 
days post vac) 
= b 41·32 (37.54, 44.72) 32·00 (22·00, 45·00) 43·27 (38·13, 48·42) 32·00 (22·00, 64·00) 38·42 (33·51, 43·33) 32·00 (22·00, 45·00) 
 YF Ab fold 






Male – 52% 
  
Female – 48% 
 
 Age (months) 9·04 (9·01, 9·08) 9·00 (9·00, 9·00) 9·04 (9·00, 9·08) 9·00 (9·00, 9·00) 9·05 (9·00, 9·10) 9·00 (9·00, 9·00) 
 Weight (kg) 8·01 (7·84, 8·18) 7·90 (7·20, 8·80) 8·20 (7·95, 8·44) 8·00 (7·50, 8·90) 7·81 (7·57, 8·05) 7·70 (7·00, 8·40) 
 Height (cm) 70·6 (70·2, 71·0) 70·0 (69·0, 72·0) 71·1 (70·6, 71·6) 70·4 (69·5, 73·0) 70·1 (69·6, 70·7) 70·0 (68·5, 71·3) 
 Weight for age 
z-score -0·70 (-0·88, -0·51) -0·81 (-1·56, 0·07) -0·84 (-1·11, -0·57) -0·98 (-1·56, 0·00) -0·53 (-0·78, -0·27) -0·69 (-1·34, 0·17) 
 Height for age 
z-scores -0·23 (-0·40, -0·06) -0·43 (-0·88, 0·46) -0·42 (-0·65, -0·18) -0·70 (-1·15, 0·46) -0·03 (-0·27, 0·21) -0·06 (-0·68, 0·48) 
 Weight for 
height z-score -0·92 (-1·13, -0·72) -1·03 (-1·82, 0·03) -1·00 (-1·32, -0·68) -1·17 (-1·94, 0·09) -0·82 (-1·10, -0·54) -0·88 (-1·66, -0·01) 
 YF Ab (base-
line) = a 2·77 (2·54, 3·01) 2·00 (2·00, 4·00) 2·81 (2·41, 3·22) 2·00 (2·00, 4·00) 2·75 (2·50, 3·01) 2·00 (2·00, 4·00) 
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 YF Ab (28 
days post vac) 
= b 27·30 (18·40, 36·22) 11·00 (6·00, 22·00) 32·35 (15·93, 48·76) 16·00 (6·00, 22·00) 22·60 (15·58, 29·61) 11·00 (6·00, 22·00) 
 YF Ab fold 
change a to b 11-fold (7, 15) 6-fold (2, 11) 13-fold (6, 20) 6-fold (2, 11) 9-fold (6, 12) 6-fold (3, 11) 
95% CI = 95% confidence interval 
IQR = interquartile range 
YF Ab = yellow fever antibody 
N = number of observations 
 
4.1.1 Antibody responses and seroconversion rates for yellow fever 
Mean and median antibody titres were statistically significantly higher in the Malian cohort both 
pre-and post-vaccination (p = <0·001 and p=0·002 respectively) as shown in Table 4.1 and Fig-
ure 4.1.  There were no significant differences in age, weight, height and z-scores between 
countries for both sexes. The overall fold changes were not significantly different between the 
two countries or between sexes, although there was a trend towards higher fold changes among 
males (Table 4.1). 
 
Figure 4.1: Post vaccination (28 days) anti-yellow fever Ab titre by country 
Median and interquartile range 
p value for country difference = 0.002. 
 
Overall, 84% of children received their yellow fever vaccine at 9 months of age. The proportion 
of children who attained seroconversion when vaccinations were given at 9 months of age was 
significantly lower in the Ghanaian than in the Malian cohort (p <0·001), (Table 4.2). The odds 



















Table 4.2:  Proportion of participants attaining a 4-fold increase (seroconversion) in anti-yellow fever anti-
body titre, stratified by age. 
Age (months) Overall Ghana Mali 
 N Proportion (95% CI) N Proportion (95% CI) N Proportion (95% CI) 
9 330 78·5 (73·7, 82·8) 152 63·8 (55·6, 71·4) 178 91·0 (85·8, 94·8) 
10 36 80·6 (64·0, 91·8) 7 57·1 (18·4, 90·1) 29 86·2 (68·3, 96·1) 
11 25 96·0 (79·6, 99·9) 0 -- 25 96·0 (79·6, 99·9) 
All 391 79·8 (75·5, 83·7) 159 63·5 (55·8, 71·0) 232 91·0 (86·5, 94·3) 
N = number of observations 
95% CI = 95% confidence interval 
NB: Results recorded, as ‘0’ for 2 participants so fold change could not be calculated 
P value for difference in seroconverters between countries <0.0001 
Odds of attaining a four-fold response in antibody titre was 7·97 times higher among the Malian cohort  
 
4.1.2 Influence of co-variates on antibody response rates to yellow fever vaccine: 
Of 28 children (9·5% of the cohort) who already had antibody titres above the defined threshold 
for protection prior to vaccination, between 96 and 99% were either well-nourished or only 
mildly malnourished respectively, according to their different WHO z-scores, compared to 88% 
of those who did have titres above the defined threshold. 
There was no statistically significant association of failure to seroconvert with nutritional status, 
nor were there pronounced sex differences in seroconversion rates. There was a trend for 
higher antibody titres in boys, though this did not reach statistical significance (p=0·08; Table 
4.1). 
None of the WHO defined z-score parameters for anthropometry were significantly associated 
with seroconversion. (Table 4.3) The odds of attaining seroconversion were however slightly 
higher in children with higher z-scores with all odds ratios slightly above one particularly for 













Table 4.3: Association between anthropometry z-scores and seroconversion (4-fold increase in anti-yellow fe-
ver antibody titres)     
  
   
Univariable (crude) Multivariable (adjusted) 
Covariate   N  OR (95% CI) p-value OR (95% CI) p-value 
Weight for height z-score 
 
           
  (per unit) 
 
391  1·02 (0·82 to 1·26) 0·8749 1·06 (0·85 to 1·33) 0·5855 
Weight for age z-score             
  (per unit) 
 
393  1·13 (0·88 to 1·44) 0·3352 1·20 (0·92 to 1·56) 0·1716 
Height for age z-score             
  (per unit) 
 
393  1·26 (0·98 to 1·63) 0·0697 1·31 (1·00 to 1·72) 0·0501 
N = number of observations; OR = Odds ratio; 95% CI = 95% confidence interval 
Results of separate uni- and multi-variable mixed-effects logistic regression, with random effects for country 
Multi-variable model additionally adjusted for pre vaccination titres, age, sex and season. 
 
Children with lower pre-vaccination titres had higher odds of attaining four-fold titre responses 
(seroconversion) post vaccination (Table 4.3).  
Table 4.4 shows the full model, including all co-variates exploring the relationship of the co-vari-
















Table 4.4: Association between weight for height z-score and seroconversion following yellow fever vaccine (N 




None of the WHO z-score parameters for nutritional status was significantly associated with an-
tibody titres above the defined threshold for protection following vaccination. Like in the analysis 
for seroconversion, the trend for higher responses was again observed at higher z-scores with 





    
   
Univariable (crude)                      Multivariable (adjusted) 
  Covariate N  N-pos. %-pos. OR (95% CI) p-value OR (95% CI) p-value 
  Weight for height z-score 
 
            
    (per unit)  -   -   -  1.02 (0.82 to 1.26) 0.8749 1.06 (0.85 to 1.33) 0.5855 
  Log2 pre-vacc. titre 
  
           
    (per unit)  -   -   -  0.31 (0.19 to 0.50) <0.0001 0.30 (0.18 to 0.50) <0.0001 
  Age 
   
           
    (per month)  -   -   -  1.07 (0.56 to 2.04) 0.8317 0.99 (0.51 to 1.94) 0.9796 
  Sex 
   
           
    male* 211 172 81.52             1.00   -        -     -               1.00   -        -     -   
    female 180 142 78.89 0.90 (0.53 to 1.53) 0.6992 0.92 (0.53 to 1.59) 0.7595 
  Season 
   
           
    dry* 243 198 81.48             1.00   -        -     -               1.00   -        -     -   
    rainy 148 116 78.38  0.76 (0.45 to 1.31) 0.3285 1.04 (0.59 to 1.84) 0.8935 
  N = number of observations; N-pos. = number seroconverted; %-pos. = percent seroconverted;    
  OR = odds ratio; 95% CI = 95% confidence interval   
 
    
  * Reference stratum 
   
    
 
    
          NB: Uni- and multi-variable mixed-effects logistic regression results, with random effects for country, 
          multi-variable model adjusted for all variables shown. 
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Table 4.5: Association between anthropometry z-scores and defined threshold (1:5) for protection from yel-
low fever  
     
    
 
    
  
   





OR (95% CI) p-value OR (95% CI) p-value 
Weight for height z-score 
 
           
  (per unit) 
 
391  1·00 (0·77 to 1·30) 0·9843 1·02 (0·78 to 1·33) 0·8986 
Weight for age z-score             
  (per unit) 
 
393  1·09 (0·81 to 1·47) 0·5488 1·13 (0·84 to 1·53) 0·4186 
Height for age z-score             
  (per unit) 
 
393  1·24 (0·91 to 1·70) 0·1771 1·29 (0·93 to 1·80) 0·1265 
   
N = number of observations; OR = Odds ratio; 95% CI = 95% confidence interval 
Uni- and multi-variable mixed-effects logistic regression results, with random effects for country, 
Multi-variable model additionally adjusted for pre vaccination titres, age, sex and season. 
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    NB: Uni- and multi-variable mixed-effects logistic regression results, with random effects for country, 
    multi-variable model adjusted for all variables shown. 
  
 
Table 4.6 shows the full model, including all co-variates exploring the relationship of the covari-
ates with weight for height z scores. The other WHO z score criteria gave similar results. Pre-
vaccination titres, age, sex and season were not significantly associated with protective anti-
body titres (Table 4.6).  
 
Similarly, no significant associations were noted when fold change was considered as a contin-
uous variable except that – like in the seroconversion analyses – pre-vaccination titres again 
significantly influenced the fold change in antibody titres (p <0·001, Table 4.7 and 4.8). The sea-
son of vaccination was correlated for univariate analysis only with slightly better fold change in 






Table 4.6 : Association of weight for height z-score with threshold for protection from yellow fever (N = 391; N-
pos. = 348; %-pos. = 89.00)    
    
   
Univariable (crude) Multivariable (adjusted) 
  Covariate N  N-pos. %-pos. OR (95% CI) p-value OR (95% CI) p-value 
  Weight for height z-score 
 
            
    (per unit)  -   -   -  1.00 (0.77 to 1.30) 0.9843                     1.02 (0.78 to 1.33) 0.8986 
  Log2 pre-vacc. titre 
  
            
    (per unit)  -   -   -  0.74 (0.42 to 1.30) 0.2972                       0.71 (0.40 to 1.25) 0.2366 
  Age 
   
            
    (per month)  -   -   -                         1.38 (0.47 to 4.07) 0.5625                       1.39 (0.46 to 4.17) 0.5586 
  Sex 
   
            
    male* 211 191 90.52               1.00   -        -     -                 1.00  -        -     -   
    female 180 157 87.22 0.76 (0.39 to 1.48) 0.4161 0.76 (0.39 to 1.48) 0.4164 
  Season 
   
            
    dry* 243 214 88.07                         1.00 -        -     -                            1.00  -        -     -   
    rainy 148 134 90.54 1.25 (0.62 to 2.54) 0.5274 1.38 (0.67 to 2.84) 0.3796 
  N = number of observations; N-pos. = number with protection; %-pos. = percent with protection;    
  OR = odds ratio; 95% CI = 95% confidence interval        
  * Reference stratum             
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Table 4.7: Association between anthropometry z-scores and post vaccination log2 fold change in anti-yellow 
fever antibody titres  
    
  
Univariable (crude) Multivariable (adjusted) 
  Covariate 
 
N Coef.  (95% CI) p-value Coef. (95% CI) p-value 
  Weight for height z-score            
    (per unit) 
 
391 0·07 (-0·02 to 0·16) 0·1551 0·04 (-0·04 to 0·12) 0·3330 
  Weight for age z-score            
    (per unit) 
 
393 0·08 (-0·03 to 0·18) 0·1394 0·06 (-0·03 to 0·16) 0·1912 
  Height for age z-score            
    (per unit) 
 
393 0·04 (-0·07 to 0·14) 0·4985 0·05 (-0·04 to 0·14) 0·2727 
   
N = number of observations; 95% CI = 95% confidence interval; Coef = coeficient 
Uni- and multi-variable mixed effects linear regression results, with random effects for country, 

























Table 4.8: Association of weight for height z-score with log2 fold change in anti-yellow fever IgG antibody (N 




4.2 Nutrition and antibody responses to measles vaccine 
Data from 1,105 infants from Mali was utilized to explore the relationship between measles vac-
cine responses and anthropometry z scores. 
The mean age in this cohort was 9.3 months, with mean pre vaccination antibody concentra-
tions of 57.87 (48.67 – 67.08) and mean fold change in antibody concentration at 28 days of 
17.3 (16.8 – 17.8) with a mean concentration of 872.9 (848.7 – 897.2). The mean antibody con-
centration 6 months post vaccination was 665.0 (633.9 – 696.1). Other cohort characteristics 
are summarized in Table 4.9. 
 
 
    
  
Univariable (crude) Multivariable (adjusted) 
 
  Covariate N  Mean Coef. (95% CI) p-value Coef. (95% CI) p-value 
 
  Weight for height z-score            
 
    (per unit)  -   -  0·07 (-0·02 to 0·16) 0·1551 0·04 (-0·04 to 0·12) 0·3330 
  Log2 pre-vacc. titre 
 
           
 
    (per unit)  -   -  -0.71 (-0.95 to -0.46) <0.0001 -0.91 (-1.15 to -0.67) <0.001 
 
  Age 
  
           
 
    (per month)  -   -                                      0.23 (0.04 to 0.42) 0.0185 0.03 (-0.15 to 0.20) 0.7752 
 
  Sex 
  
           
 
    male* 211 14.18                  0.00   -     -                       0.00   -     -   
 
    female 180 11.46                                     -0.13 (-0.34 to 0.08) 0.2309 -0.07 (-0.26 to 0.11) 0.4364 
 
  Season 
  
           
 
    dry* 243 13.98                 0.00   -     -                         0.00   -     -   
 
    rainy 148 11.21     -0.24 (-0.45 to -0.02) 0.0326     -0.00 (-0.20 to 0.20) 0.9726 
 
  
N = number of observations; Mean = mean log2 fold change; Coef. = coefficient; 95% CI = 95% confidence interval 
* Reference stratum 
 
          NB: Uni- and multi-variable mixed-effects linear regression results, with random effects for country, 
         multi-variable model adjusted for all variables shown. 
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Table 4.9: Cohort Characteristics – measles vaccine response 
 Overall  Male (51%)  Female (49 %)  
N = 1,105 Mean (95% CI) Median (IQR) Mean (95% CI) Median (IQR) Mean (95% CI) Median (IQR) 
Age (months) 9.34 (9.30 – 
9.38) 
9.00 (9.00 – 
10.00) 
9.36 (9.30 – 
9.41) 
9.00 (9.00 – 
10.00) 
9.32 (9.27 – 9.38) 9.00 (9.00 – 9.00) 
Weight (kg) 8.34 (8.29– 
8.40) 
8.20 (7.70 – 
8.90) 
8.59 (8.52 – 
8.67) 
8.50 (8.00 – 
9.10) 
8.08 (8.00 – 8.15) 8.00 (7.40 – 8.60) 




71.5 (71.5 – 
71.9) 
72.0 (70.0 – 
73.0) 
70.6 (70.4 – 70.8) 71.0 (69.0 – 72.0) 
Weight for age 
z score 
-0.37 (-0.43 to -
0.32) 
-0.42 (-0.98 to 
0.18) 
-0.46 (-0.54 to -
0.38) 
-0.53 (-1.09 to 
0.10) 
-0.28 (-0.36 to -
0.21) 
-0.31 (-0.87 to -
0.27) 
Height for age 
z scores 
-0.15 (-0.21 to -
0.09) 
-0.06 (-0.88 to 
0.46) 
-0.31 (-0.40 to -
0.23) 
-0.43 (-1.00 to 
0.46) 
-0.03 (-0.05 to 
0.11) 
-0.06 (-0.60 to 
0.77) 
Weight for 
height z score 
-0.55 (-0.61 to -
0.49) 
-0.57 (-1.18 to 
0.07) 
-0.56 (-0.64 
 to -0.47) 
-0.57 (-1.18 to 
0.03) 
-0.54 (-0.62 to -
0.45) 
-0.56 (-1.20 to 
0.12) 
Measles Ab 
(baseline) = a 
57.87 (48.67 – 
67.08) 
50.00 (50.0 – 
50.0) 
 
52.43 (47.79 – 
57.06) 
50.00 (50.0 – 
50.0) 
63.54 (45.37 – 
81.72) 
50.00 (50.00 – 
50.00) 
 
Measles Ab (28 
days post vac) 
= b 
872.9 (848.7 – 
897.2)  
820.4 (581.4 – 
1089.6) 
841.6 (809.1 – 
767.9) 
803.6 (567.3 – 
1065.0) 
905.6 (869.7 – 
941.5) 
847.9 (599.1 – 
1134.8) 
Measles Ab (6 
months post 
vaccination N = 
1,081) = c  
665.0 (633.9 – 
696.1) 
535.7 (338.0 - 
831.2) 
623.7 (580.0 – 
667.4) 
494.3 (314.2 - 
764.2) 
707.3 (663.1 – 
751.5) 
578.5 (373.9 - 
896.7) 
Measles Ab 
fold change a to 
b 
17.3 (16.8 – 
17.8)   
16.3 (11.6 – 
21.7) 
16.7 (16.1 – 
17.4) 
16.1 (11.3 – 
21.3) 
17.8 (17.1 – 18.5)     16.7 (11.8 – 22.4) 
Measles Ab 
fold change a to 
c 
13.5 (12.7 – 
14.2) 
10.6 (6.8 – 
16.3) 
12.4 (11.5 – 
13.3) 
10.0 (6.3 – 
15.5) 
14.5 (13.3 – 15.7) 11.4 (7.4 – 17.3) 
Measles antibody expressed in mIU/ml 
95% CI = 95% confidence interval 
IQR = interquartile range 
N = number of observations 
NB: Pre-vaccination IgG concentration was 50.0 for 1,092 of the 1,105 observations thus the median values of 50.0 with 95%Ci of 50.0    
to 50.0. The value of 50.0 was assigned if the value fell below the limit of detection 
 
 
4.2.1 Antibody responses and seroconversion rates for measles vaccine 
There was a general trend towards higher antibody concentrations in females compared to their 
male counterparts.  
31 
Of this cohort 98.3% attained seroconversion 28 days post vaccination. Similar proportions at-
tained seroconversion across the different age groups (Table 4.10). The mean and median anti-
body concentrations were also similar across the ages. The majority (74.3%) of the cohort re-
ceived the measles vaccine at 9 months of age. 
Table 4.10:  Proportion of participants attaining a 4-fold increase in antibody concentration (serocon-
version) 28 days following measles vaccination. 
Age (months) N (%) Proportion (95% CI) 
9 822 (74.4) 98.3 (84.9 – 89.6) 
10 190 (17.2) 98.4 (95.5 – 99.7) 
11  93 (8.4) 97.9 (92.4 – 99.7) 
All 1,105 (100) 98.3 (97.3 – 99.0) 
N = number of observations 
95% CI = 95% confidence interval 
 
 
Twenty-eight days post vaccination only 2 children (0.2%) still had Ab concentrations below the 
definate threshold for protection. Both of these children were male and aged 9 months at vac-
cination. By 6 months post vaccination, however 30 children (2.8%) overall had concentrations 
below 120mIU/ml. Eighteen (60%) of these were male. There was no observed trend linked to 
the nutritional z scores for these children whose IgG antibody concentrations fell below the 
threshold at either time point. 
4.2.2 Effect of covariates on antibody responses to measles vaccine 
Pre-vaccination at 9 – 11 months of age, 99.6% of these children had anti-measles IgG less 
than the defined threshold for protection of 120mIU/ml. Of the 4 infants with concentrations 
above this defined threshold of protection, 1 was aged 10 months while the other 3 were 11 










Table 4.11: Association between anthropometry z-scores and threshold for seroconversion (4-fold increase in 
anti-measles antibody concentrations)  
 
 
Nineteen of the 1,105 children failed to attain seroconversion. Of this number 12 (63%) were 
male. There was no statistically significant association between the failure to seroconvert and 
nutritional status measured by anthropometry (Table 4.11)   
The children with lower pre-vaccination concentrations had higher odds of attaining a four-fold 
rise in antibody concentrations (multivariable p =0.0114 Table 4.12) Similar results were ob-











   
Univariable (crude) Multivariable (adjusted) 
Covariate   N  OR (95% CI) p-value OR (95% CI) p-value 
Weight for height z-score 
 
           
  (per unit) 
 
1,100 1.32 (0.83 – 2.09) 0.2366 1.50 (0.91 – 2.48) 0.1146 
Weight for age z-score       
  (per unit) 
 
1,105  1.17 (0.72 – 1.91) 0.5301 1.15 (0.67 – 1.97) 0.6068 
Height for age z-score       
  (per unit) 
 
1,105 0.88 (0.57 – 1.37) 0.5825 0.70 (0.43 – 1.15) 0.1599 
   
N = number of observations; OR = Odds ratio; 95% CI = 95% confidence interval 
Results of separate uni- and multi-variable logistic regression 
Multi-variable model adjusted for pre vaccination concentrations, age, sex and season of vaccination. 
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Table 4.12: Association between weight for height z-score and seroconversion following measles vaccine (N = 
1,105; N-seroconverted = 1,086, % seroconverted = 98.3%)  
 
The odds of attaining antibody concentrations above the defined threshold for protection were 
similar for all 3 z score parameters with no significant differences in attaining this threshold 






    
   
Univariable (crude)                      Multivariable (adjusted) 
  Covariate N  N-pos. %-pos. OR (95% CI) p-value OR (95% CI) p-value 
  Weight for height z-score 
 
            
    (per unit)  -   -   -  1.32 (0.83 to 2.09) 0.2366 1.50 (0.91 to 2.48) 0.1146 
  Log2 pre-vacc. titre 
  
           
    (per unit)  -   -   -  0.97 (0.93 to 1.01) <0.0001 0.00 (0.00 to 0.27) 0.0114 
  Age 
   
           
    (per month)  -   -   -  1.07 (0.56 to 2.04) 0.8317 1.22 (0.36 to 7.14) 0.5403 
  Sex 
   
           
    male* 562 550 97.88             1.00   -        -     -                1.00   -        -     -   
    female 543 536 98.71 0.93 (0.46 to 1.88) 0.8451   2.56 (0.84 to 7.81) 0.0990 
  Season 
   
           
    dry* 757 746 98.55             1.00   -        -     -                1.00   -        -     -   
    rainy 348 340 97.70 0.62 (0.25 to 1.57) 0.3165    0.47 (0.17 to 1.28) 0.1397 
  N = number of observations; N-pos. = number seroconverted; %-pos. = percent seroconverted;    
  OR = odds ratio; 95% CI = 95% confidence interval   
 
    
  * Reference stratum 
   
    
 
    
          NB: Uni- and multi-variable mixed-effects logistic regression results, with random effects for country, 
         multi-variable model adjusted for all variables shown. 
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Table 4.13: Association between anthropometry z-scores and threshold for protection 28 days post vac-
cination (anti-measles antibody concentrations of 120mIU/ml)     
  
   
Univariable (crude) Multivariable (adjusted) 
Covariate   N  OR (95% CI) p-value OR (95% CI) p-value 
Weight for height z-score 
 
           
  (per unit) 
 
1,105 0.74 (0.20 – 2.75) 0.6586 0.70 (0.17 – 2.94) 0.6221 
Weight for age z-score       
  (per unit) 
 
1,100  0.71 (0.18 – 2.84) 0.6233 0.73 (0.19 – 2.83) 0.6465 
Height for age z-score       
  (per unit) 
 
1,105 0.85 (0.22 – 3.28) 0.8125 0.86 (0.22 – 3.38) 0.8347 
   
N = number of observations; OR = Odds ratio; 95% CI = 95% confidence interval 
Results of separate uni- and multi-variable  logistic regression 
Multi-variable model adjusted for pre vaccination concentrations, season. 
 
There was no relationship between any of the examined covariates and the attainment of IgG 
antibody above the threshold defined for protection (Table 4.14). Similar results were obtained 

















Table 4.14: Association between weight for height z-score and attaining threshold for protection against mea-
sles (N = 1,105; N- above threshold = 1,103, % above threshold = 99.8%)  
 
 
None of the anthropometric z score parameters influenced the anti-measles IgG antibody 











    
   
Univariable (crude)                      Multivariable (adjusted) 
  Covariate N  N-pos. %-pos. OR (95% CI) p-value OR (95% CI) p-value 
  Weight for height z-score 
 
            
    (per unit)  -   -   -            0.74 (0.20 to 2.75) 0.6586        0.70 (0.17 to 2.94) 0.6221 
  Log2 pre-vacc. titre 
  
           
    (per unit)  -   -   -  1.21 (0.00 to 918.05) 0.9549 1.37 (0.00 to 0.4608.66) 0.9394 
  Season 
   
           
    dry* 757 746 99.87           1.00   -        -     -            1.00   -        -     -   
    rainy 348 340 97.98           0.46 (0.03 to 7.34) 0.5810          0.45 (0.03 to 7.23) 0.571 
  N = number of observations; N-pos. = number seroconverted; %-pos. = percent seroconverted;    
  OR = odds ratio; 95% CI = 95% confidence interval   
 
    
  * Reference stratum 
   
    
 
    
         NB: Uni- and multi-variable mixed-effects logistic regression results, with random effects for country, 
         multi-variable model adjusted for all variables shown. 
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Table 4.15: Association between anthropometry z-scores and log2 antibody concentrations post vaccina-
tion following measles vaccine  
  
   
Univariable (crude) Multivariable (adjusted) 
Covariate   N  Coef (95% CI) p-value Coef (95% CI) p-value 
Weight for height z-score 
 
           
  (per unit) 
 
1,100 -0.00 (-0.03 – 0.03) 0.8476 -0.00 (-0.03 – 0.03) 0.8233 
Weight for age z-score       
  (per unit) 
 
1,105  -0.01 (-0.04 – 0.02) 0.4447 -0.01 (-0.04 – 0.02) 0.4341 
Height for age z-score       
  (per unit) 
 
1,105 -0.01 (-0.04 – 0.01) 0.3259 -0.01 (-0.04 – 0.01) 0.3262 
* Reference stratum 
N = number of observations; Coef = coeficient; 95% CI = 95% confidence interval 
Results of separate uni- and multi-variable linear regression 
Multi-variable model adjusted for pre vaccination IgG concentration, age, sex and season 
 
 
Attainment of a higher anti-measles antibody concentration was significantly impacted by the 
pre vaccination concentration (p <0.001) and sex (p = 0.016) both univariably and when adjust-
ing for the other covariates and in multivariable analysis (Table 4.16). Females had significantly 
higher post-vaccination antibody concentrations and lower pre-vaccination concentration re-












Table 4.16: Association between weight for height z score and log2 anti-measles IgG concentrations (N = 
1,105; Mean = 872.9) 
* Reference stratum 
N = number of observations; Coef = coeficient; 95% CI = 95% confidence interval 
Results of separate uni- and multi-variable linear regression 
Multi-variable model adjusted for pre vaccination IgG concentration, age, sex and season 
 
Similar results as obtained 28 days post vaccination, were obtained at the extended time point 6 
months post vaccination for all the methods of assessing response and for all anthropometric 
measures. The effects of pre-vaccination concentrations on the responses at 6 months were 
however less marked (p = 0.01 and 0.07 respectively).    
5. Discussion and conclusions 
We examined the impact of nutritional status and other selected covariates on antibody re-
sponses to yellow fever and measles vaccine measured within 28 days of receiving the yellow 
fever and measles vaccine in infants from rural and urban Africa. Three hundred and ninety-
three infants were studied for yellow fever responses and 1,105 for measles responses. For the 




                             Univariable (crude)   
 
Multivariable (adjusted) 
Co variate N mean      Coef (95% CI) p-value Coef (95% CI)                         p-value 
Weight for height z 
score            -            -  -0.00 (-0.03 – 0.03) 0.8476 -0.00 (-0.03 – 0.03) 
 
0.8233 
Log2 pre-vac IgG con-





            
  (per month)      -          -   -0.12 (-0.21 to -0.02) 0.2382   0.04 (-0.04 – 0.12) 0.3357 
Sex 
 
            
  male* 562     841.0 0.00   -        -     -      0.00  -        -    
  female 543 904.1 0.02 (-0.10 – 0.14) 0.0162    0.07 (0.01 – 0.13) 0.0175 
Season 
 
            
  dry* 757 852.9  0.00 -        -     -    0.00  -        -    
  rainy        348 913.6 -0.00 (-0.13 – 0.13) 0.1273      0.05 (-0.01 – 0.12) 0.1058 
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5.1 Yellow Fever 
Prior to vaccination as expected, mean antibody titres for this cohort were below the defined 
threshold of protection of 1:5. [71] This finding suggests that the vast majority of children be-
tween the ages of 9 and 11 months are likely susceptible to yellow fever in the endemic setting 
of Ghana and Mali since neutralizing antibodies titres are considered the correlate of protection 
for yellow fever. [58-61] On the other hand, almost 10% of the infants did have pre-vaccination 
antibody titres above 1:5, indicating either natural exposure or the effect of persisting maternal 
antibodies, due to prior exposure or vaccination of the mother within routine vaccination pro-
grammes or prior natural exposure of the child to the virus. Almost all children (96%) in the 
small group with pre-vaccination titres above protective threshold were adequately nourished 
compared to 87% of those below the threshold. This may be a chance finding or suggest that 
mounting an adequate response to natural exposure may be linked to adequate nutrition. To our 
knowledge a possible relationship between nutrition and natural immunity has not been previ-
ously reported in the literature but larger cohorts would be required to confirm this finding.  
The overall antibody titres and fold changes in response to yellow fever vaccination in our co-
hort were not significantly affected by the nutritional status as characterised by weight for age, 
height for age or weight for height z-scores. This finding is very reassuring, as it implies that 
even malnourished children can mount a protective response to this vaccine. It is a limitation of 
this study, however that the number of children with z scores in the severe malnutrition range 
was very low in our cohort, and the question of nutrition and response to this vaccine may still 
benefit from more detailed testing in this specific group. This is important, given that they make 
up a larger proportion [28] (up to 50% malnourished to some degree) [25, 30] of children receiv-
ing vaccines in routine EPI programmes compared to clinical trials, where malnutrition is often 
an exclusion criterium. Most of the malnourished children in the MenAfrivac trials happened to 
develop growth faltering during the trial, in line with the usual observation of malnutrition occur-
ring at the time of weaning.  
However, the trend for improved seroconversion especially in children with higher z-score for 
height for age (multivariable p = 0.0501) indicates that chronic malnutrition which this parameter 
measures, may play a role, and hence it is important to assess yellow fever responses in a 
larger group of children with severe/chronic malnutrition. In addition to measuring vaccine titres 
and rates of seroconversion, functional antibody studies and more detailed investigations of B 
cell memory and repertoire might also be needed to conclude on the impact of nutritional factors 
on long-term immunity and protection. In addition, nutritional factors other than anthropometry 
such as micronutrient deficiencies might also play a role in vaccine responses. The potential 
clinical significance of all these factors needs to be assessed in longitudinal cohort studies or as 
part of systematic routine surveillance systems. 
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Examining the longevity of yellow fever antibody titres would be of interest given that a recent 
systematic review suggests that the longevity of vaccine response may be impaired when vac-
cines are given to the malnourished [28]. This question is particularly important considering 
WHO’s recent recommendation of changing from 10 yearly doses of YF vaccine to a single 
dose of yellow fever vaccine to achieve life-long protection. In addition, there are a number of 
ongoing studies to assess if full protection can be achieved by fractional dosing, driven by the 
shortage of the yellow fever vaccine supplies.  
Following vaccination, over 79% of the overall cohort attained seroconversion rates of a four-
fold rise in antibody titres in our cohorts. This is lower than previous reports of 95% seroconver-
sion in The Gambia when yellow fever vaccine was administered concomitantly with measles, 
rubella and IPV vaccines [49]. When seroconversion rates were disaggregated by country, the 
seroconversion rates in Mali alone were more comparable to this prior finding. A remarkable 
finding which has also been previously reported [57] is the marked difference in seroconversion 
rates between the Ghanaian and Malian cohorts: barely 60% of the Ghanaian infants attained 
seroconversion compared to roughly 90% of the Malians. This is especially striking as pre-vac-
cination titres were only slightly lower in Ghana. Lower pre vaccination titres has already been 
shown to be related to higher seroconversion suggesting that this difference between countries 
may not be purely due to an environmental effect due to the differences in location from which 
these participants were recruited. If differences in antibody longevity were to be shown between 
those with lower seroconversion rates and the group with adequate seroconversion, a booster 
dose needs to be considered to protect these individuals.  
Given that up to 20% of infants overall do not achieve seroconversion, as shown in our dataset, 
the protective efficacy of the vaccine at a population level within the sub-region might also be 
jeopardised, especially if population coverage rates are suboptimal as they often are.  The situ-
ation would be even more concerning in the Ghanaian cohort where close to 40% did not sero-
convert.  
It is of note that the children in these 2 countries received different preparations of yellow fever 
vaccines, which might have been a significant contributing factor. The two yellow fever vaccines 
contain antigens with slightly different genomic sequences which  are not considered of identical 
genotype or phenotype [81]. They also differ in the passage level [82] and envelope protein gly-
cosylation sites. Although these vaccines have been compared for non-inferiority in clinical eval-
uation, they have never been compared directly side by side [83]. Our findings support a need 
for such side-by-side evaluation, given that countries usually decide what vaccine to use for lo-
gistical and cost reasons. Such data could influence decision-making with regards to what vac-
cine to use.  
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Another potential contributing reason for the observed inter country variability could be the fact 
that the children in Ghana were from a rural area while those in Mali were recruited from an ur-
ban setting. This may suggest that other nutritional (other than anthropometric measures) or en-
vironmental variables including differential prior exposure to other infections or infestations 
which may include exposure to other flavi viruses play a role. Prior flavi virus exposure has 
been linked to limited severity of yellow fever infection[84] and may also impact response to the 
yellow fever vaccine.  
Examining other vaccine responses between these 2 cohorts particularly where the same vac-
cine was used, and likely causes for these differences or their generalisability should be further 
explored. These comparisons would be useful to better delineate these marked differences in 
proportion of seroconversion. 
The season of vaccination had no impact on responses in our cohort, which differs from some 
previous studies showing poorer vaccine response during the lean (rainy season) months espe-
cially in rural settings [50].  
It is important to note that unlike the responses observed in relation to some other vaccines [46, 
47], there were no significant sex differences in the fold change or quantitative response to yel-
low fever, as also reported previously [57]. There was however a trend towards higher re-
sponses in boys. This is different from previous reports of trends for higher responses in fe-
males to vaccines in general due to immunological difference between the sexes,[46, 47] but in 
accordance with previous findings from Pfister et al. who found higher antibody response in 
males for two yellow fever vaccines [83]. Taken together, these findings suggest that sex differ-
ences in vaccine responses are vaccine specific and probably quite complex.  
The odds of attaining a fourfold response in antibody titre were significantly higher in infants 
who had lower pre-vaccination antibody concentrations. This is not surprising as the magnitude 
of response needed to attain a fourfold response would be much lower in children with lower 
pre-vaccination titres. This finding is also in keeping with previous results from 12 to 23-month-
old Gambian children following receipt of the MenAfriVac vaccine [51]. In addition, the odds of 
attaining an antibody titre post vaccination above the defined threshold for protection was signif-
icantly higher in the Malians, which is probably partly a consequence of the higher pre-vaccina-
tion antibody titres in these children and related to the factors discussed above.  
 
Limitations: 
Many more infants in this study (84%) received the yellow fever vaccine at 9 months of age and 
only Mali vaccinated infants aged 11 months. There were relatively few malnourished children. 
Thus, comparisons between the ages and nutritional groups would benefit from reassessment 
in studies specifically powered for these outcomes.  
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5.2 Measles  
We examined the impact of nutritional status and other selected covariates on antibody re-
sponses to measles vaccine measured within 28 days of receiving the measles vaccine in 1,105 
infants from urban Africa. Data was also available at an extended time point 6 months post vac-
cination for 1,081 infants. 
Prior to vaccination the majority of infants had serum antibody titres well below the defined 
threshold for protection of 120mIU/ml [78-80, 85]. This finding confirms that virtually all children 
in this region are susceptible to measles infection at 9 to 11 months of age, supporting the need 
for timely vaccination. The almost total absence of concentrations above the defined threshold 
for protection may support recent studies advocating for earlier measles vaccination given the 
low sero prevalence of measles antibody concentrations [80, 86] and the appreciable immune 
responses to vaccination in children younger than 9 months [87, 88]. This suggestion of a need 
for earlier vaccination may also be supported by a study which documented that girls loose ma-
ternal antibody faster than boys and may be more susceptible to infection prior to 9 months of 
age [88]. Our findings also do not suggest better responses with increasing age with similar se-
roconversion rates at 9, 10 and 11 months. While this may be different prior to 9 months of age, 
early measles vaccination may be an important consideration given the recent worldwide mea-
sles outbreaks including in children too young to have been vaccinated in routine programmes 
[66, 70]. The use of boosting doses currently recommended by WHO [37] should also ensure 
that adequate antibody concentrations are ultimately sustained to provide long lasting protection 
especially where initial vaccination happens early. 
None of the anthropometric measures for malnutrition significantly influenced the antibody re-
sponse to measles vaccine. An impact of nutrition measured by anthropometry on measles vac-
cine responses has previously been documented [72] in children from Uganda based on weight 
for height/length z scores. The Ugandan study reports infant wasting as being associated with 
lower measles specific IgG antibody concentrations. This finding differs from our own data, and 
it may suggest that there are regional or genetic differences in the factors influencing vaccine 
responses. Its clinical significance will need to be further explored but it is reassuring that pro-
tective concentrations are generally being attained. 
The significantly higher antibody concentrations post vaccination in girls which we observed has 
been previously reported in a cohort of similar age from Spain [89]. Similar patterns were also 
observed for rubella and mumps vaccines [89], and a study of the now discontinued Edmon-
ston-Zagreb strain of measles vaccine reported excess mortality in girls 3 years post vaccina-
tion, suspected to be linked to the higher post vaccination antibody concentrations following this 
high dose vaccine [90]. Taken together, one would wonder if some precision vaccinology 
whereby vaccines with different antigen concentrations are used in male versus female children 
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such that females receive lower dose vaccines may be of benefit to optimize the use of the ex-
tremely useful measles vaccine. This may be a solution for vaccine shortage situations where 
fractional doses could be considered in girls. A similar dose modification strategy was recently 
successfully implemented for flu vaccines for the elderly [91]. The use of such varied dose inter-
ventions would however be a subject for further studies. 
As with yellow fever vaccine lower pre-vaccination concentrations for measles correlated with 
lower post vaccination responses but better seroconversion. We have also previously docu-
mented this for MenAfriVac as discussed above [51].  The consistency of this finding for differ-
ent antigens suggests that lower antibody concentrations at the point of vaccination correlate 
with lower post vaccination concentration. It is however easier to then attain a 4-fold increase in 
post vaccination titres which is one of the measures of vaccine immunogenicity. This may not 
however correlate with attainment of antibodies above a defined threshold and suggests that 
one parameter in isolation may not be sufficient to comment on vaccine immunogenicity. For 
antigens like measles where a definite correlate of protection exists, this may be less relevant 
than for antigens where there is no definite correlate of protection. 
Six months post vaccination, there was as expected a slight decline in IgG antibody concentra-
tions. Similar trends for association as with the 28-day post vaccination time point were noted at 
6 months. Of note, 30 (2.7%) of the 1,105 infants no longer had antibodies above the definite 
threshold defined for protection compared to only 2 children at 28 days post vaccination. This 
finding supports the recommendation for booster vaccination in infants [37] as these concentra-
tions are likely to wane further over time. 
  
Limitations: 
As with the data for yellow fever responses, most infants in this study (77%) received the mea-
sles vaccine at 9 months of age. There were also relatively few malnourished children. Thus, 
comparisons of the effect of nutrition would benefit from further exploration in larger studies, suf-
ficiently powered to test such specific co-variables.  
 
5.3 Conclusions 
In conclusion, yellow fever seroconversion rates were significantly lower in Ghanaian children 
compared to infants in Mali. They were unaffected by season of vaccination, sex or nutritional 
status, although there was a trend to higher titres in males and in children with higher height for 
age z-scores, which is a measure of chronic malnutrition. There may also be a relationship be-
tween the response to natural exposure and nutritional status.  
Given the low seroconversion rates in Ghana in particular and the implications for protection at 
both the personal and population level, our data support the requirement for further analyses of 
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existing data and samples from young infants in different regions in order to be confident that 
the WHO recommendation of a single vaccine dose of yellow fever vaccine is indeed providing 
the intended level of protection for life at both individual and population level. This is further sup-
ported by the longitudinal anti-yellow fever antibody titre data which we present below. Such 
studies should also include longitudinal follow up studies to measure longevity of responses. 
There may be further need to systematically examine differences between the yellow fever vac-
cine strains contained in the variety of yellow fever vaccine preparations to guide best use of the 
available vaccines by decision makers.  
 
Seroconversion rates to measles vaccine on the other hand were not significantly impacted by 
anthropometric measures of malnutrition. This is a reassuring finding. Of note, virtually all chil-
dren in this cohort had pre- vaccination IgG antibody concentrations below the definite threshold 
for protection implying that infants at this age are vulnerable to infection and may support the 
call for earlier measles vaccine doses. In addition, the observed sex differences would benefit 
from further studies to understand the factors mediating these differences and assess their clini-
cal relevance- if any. Understanding the dynamics mediating these differences would help tailor 
immunization programmes to the population and could potentially inform future vaccine devel-
opment should precision vaccinology for boys versus girls be considered. By 6 months post-
vaccination, a small proportion no longer had protective immunity. This supports the need for 
booster vaccines. 
 
6 Longevity of response to yellow fever vaccine 
6.1 Background 
There is ongoing debate regarding the longevity of response to a single yellow fever vaccine 
and this has been identified as a priority research area by WHO, particularly in special groups 
such as infants, immunocompromised and individuals who received fractional doses of the vac-
cine [58, 59, 62]. Expanding the body of knowledge in this area is crucial to guiding future policy 
on the use of the vaccine. This is particularly important as the current WHO recommendation of 
a single vaccine dose for life may leave millions vulnerable to infection particularly in endemic 
areas, should they not mount an appreciable response, or the persistence of protection be lim-
ited. 
The current evidence on antibody longevity following vaccination is varied. A study from Brazil 
reports only 69% of children had protective titres 10 years post vaccination [85, 92]. In Dutch 
adults however it was demonstrated that following 1 dose of yellow fever vaccine, over 98% of 
adults retained protective titres up to 10 years post vaccination following a fractional dose [93]. 
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This, contrasts with 82% of US adults retaining protective titre following 1 standard dose of yel-
low fever vaccine [94]. There is however a paucity of data from children which is important es-
pecially in endemic settings where the single dose for life would be given in infancy when re-
sponses may not be the same as for adults. 
6.2 Rationale and methods 
The low seroconversion rate for yellow fever vaccine response in Ghana calls into question the 
longevity of protection in the children in that cohort. This is particularly so, because antibody re-
sponses to some vaccines including those to yellow fever vaccine tend to dip after an initial rise. 
The initial peak is often maximal at around 28 days in the immediate post vaccination period 
and drops of within the first 6 months to 1 year with a subsequent plateau [95, 96]. Thus, the an-
tibody concentrations may be even lower in this cohort following a period of time as the re-
sponses reported above should be at about the point of maximal responses. Samples from the 
same Ghanaian and Malian cohort described at 28 days post vaccination time point above were 
not available to assess longevity of response. Samples for an extended time point for the Gha-
naian cohort are however currently being collected by another team. 
In order to address the important question of longevity of protection, I assayed yellow fever anti-
body responses in another cohort of African children from Gambia and Mali for whom banked 
serum samples were available. This separate cohort has been described above in section 3.1.1 
– Study pers-002-003. The assays were done in the same laboratory as the assays for the Ma-
lian and Ghanaian cohorts reported above, using similar methods as follows. Titres of neutraliz-
ing antibodies to yellow fever virus were determined by a microneutralization assay. To do this, 
100 TCDI50 infectious doses of a yellow fever virus suspension (strain YF-213, Robert Koch In-
stitute) were reacted with serial two-fold dilutions of sera before inoculation into Vero cells cul-
tured in 96-well plates. The cells were microscopically examined for cytopathic effect after 
seven days. Reference serum samples were run with each plate to ensure suitability of assay 
and minimize batch effects. 
Baseline titres and baseline anthropometry were not available for correlation with these titres. 
The age at vaccination was unavailable. These children had all been vaccinated as part of rou-
tine EPI programmes prior to enrolment in the study. Prior vaccination with all EPI vaccines due 
by 12 months of age which include yellow fever vaccine was a prerequisite for trial enrolment. 
Prior vaccination was confirmed from immunization records but not correlated with a date of 
birth which would have enabled calculation of age at receipt of yellow fever vaccine as this out-





This cohort included 481 children of which 53.4% were males. The mean antibody titres to 
yellow fever vaccine by microneutralization five to six years post vaccination in children who had 
received a single dose of yellow fever vaccine within routine EPI programmes prior to 12 to 23 
months of age was 26.7 {95% CI (21.7 – 31.7)}. The median antibody titre was 12.0 {interquar-
tile range (4.0 – 22.0)}. Of note, 21.8% of the cohort had undetectable antibody titres at this time 
point, with another 5% revealing concentrations below the defined titre for protection of 1:5. An-
tibody titres by country are summarized in Table 6.1.  
The antibody titres did not differ significantly by country (p = 0.09) although there was a trend to 
higher titres in the Malian cohort. 
 
Table 6.1: Persistence of anti-yellow fever antibody titres 5 – 6 years post vaccination 
 Mean (95% CI) Median (IQR) Percentage with  
undetectable antibody (%) 
Percentage with antibody  
below protective threshold (%) 
Overall (N = 481) 26.7 (21.7 – 31.7) 12.0 (4.0 – 22.0) 21.8 26.8 
Mali (N =238) 30.5 (21.5 – 39.5) 12.0 (0.0 – 22.0) 25.6 28.6 
Gambia (N = 243) 23.0 (18.3 - 27.7) 12.0 (5.0 – 22.0) 19.7 25.1 
95% CI = 95% confidence interval 
IQR = interquartile range 
YF Ab = yellow fever antibody 
N = number of observations 
NB: Percentage with titres below the protective threshold includes those with undetectable titres 
 
The distribution of titres is represented in figure 6.1 revealing non-statistically significantly higher 
titres in Mali and showing the generally low antibody tires in these children 5 to 6 years post 





Figure 6.1 Distribution if anti-yellow fever antibody titre by Country 
Kernel density: non-parametric estimation of probability density function of anti-yellow fever titre 
NB: P value for difference in antibody titre between countries = 0.1401 
 
Sex, country and time since vaccination did not affect the longevity of antibody titre in uni- or 
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Table 6.2 Association of covariates at time of vaccination with log2 anti-yellow fever antibody titres 5 – 6 years post vac-
cination 
 
NB: Age and sex missing for 1 participant 
* Reference stratum 
N = number of observations; Coef = coeficient; 95% CI = 95% confidence interval 
Results of separate uni- and multi-variable linear regression 
Multi-variable model adjusted for, age, sex and season of vaccination and time since vaccination 
 
 
The odds of maintaining an antibody titre above the defined threshold of protection of 1:5 was 











Univariable (crude)                      Multivariable (adjusted) 
Covariate             N Coef. (95% CI) p-value Coef. (95% CI) p-value 
Sex 
  
           
  male* 
 
256             0.00   -        -     -             0.00   -        -     -   
  female 
 
224 1.94 (-8.17 to 12.06) 0.7061           0.03 (-0.17 to 0.03) 0.7407 
Season 
  
           
  dry* 
 
311              0.00   -        -     -             1.00   -        -     -   
  rainy 
 
170 -3.27 (-13.8 to 7.27) 0.5425          -0.05 (-0.27 to 0.17) 0.6570 
Country       
   Mali*  232                   0.00   -        -   -               0.00  -        -   -   




-                 -0.04 (-1.30 -1.21)                 0.9477                 0.19 (-1.73 to 2.11) 0.8475 
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Table 6.3 Association of covariates at time of vaccination with maintaining a threshold of anti-yellow fever antibody titres 
of 1:5 or more 5 – 6 years post vaccination 
 
NB: Age and sex missing for 1 participant 
* Reference stratum 
N = number of observations; Coef = coeficient; 95% CI = 95% confidence interval 
Results of separate uni- and multi-variable logistic regression 
Multi-variable model adjusted for, age, sex and season of vaccination and time since vaccination 
 
6.4 Discussion  
Our data suggest that over 25% of infants who received a single dose of yellow fever vaccine as 
part of routine EPI schedules are unprotected by 5 – 6 years after vaccination defined by corre-
late of protection of titres of 1:5. This worrying finding has significant implications for defining 
vaccination policies for infants who received yellow fever vaccine as part of routine EPI pro-
grammes in view of WHO’s current recommendations of a single vaccine dose for life. Recent 
studies following fractional dosing of yellow fever vaccine to Dutch adults demonstrated that up 
to 10 years post vaccination 98% of the individuals vaccinated were still protected [93]. The 
sample size was however small (40 individuals) and represented only 48% of the original recipi-
ents of the vaccine [93]. While the findings following a fractional dose of yellow fever vaccine 
differ from ours, where a full dose of vaccine was administered, longevity following fractional 
doses may be worse than that following a full dose. However, vaccines were administered to 
  
   
Univariable (crude)                      Multivariable (adjusted) 
Covariate   N mean OR ((95% CI) p-value OR (95% CI) p-value 
Sex 
   
           
  male* 
 
256 25.8           1.00   -        -     -             1.00   -        -     -   
  female 
 
224      27.8            0.97 (0.65 to 1.45) 0.8689           0.97 (0.65 to 1.45) 0.8806 
Season 
   
           
  dry* 
 
311 27.9           1.00   -        -     -             1.00   -        -     -   
  rainy 
 
170      24.6            0.86 (0.56 to 1.30) 0.4634            0.83 (0.54 to 1.27) 0.3943 
Country        
   Mali*  232        30.5                1.00   -        -   -               1.00 -        -   -   




-               -                   0.99 (0.94 to 1.04)                 0.7898                 0.96 (0.00 to 1.27) 0.3943 
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different age groups: – adult vs infant and different settings – non-endemic Europe versus en-
demic Africa. These factors may also explain difference, given the entirely different natural ex-
posure between non-endemic and the endemic settings and potentially between age groups. A 
study reporting antibody persistence in US adults following a full dose of yellow fever vaccine 
reports that all individuals who received multiple doses of yellow fever vaccine had protective 
titres irrespective of the time since previous vaccination. Of individuals who had received only 1 
dose however, if that dose was less than 10 years from the time of testing, 94% of them had 
protective titres. When 10 or more years had elapsed however, only 82% had protective titres 
[94]. This study does therefore suggest that even in adults booster vaccinations may still be 
warranted in certain populations, as argued in a recent opinion piece by a prominent vaccinolo-
gist [85]. There is however a paucity of data on persistence of immunity to yellow fever in chil-
dren and thus our findings are important and timely and will inform the discussions around fu-
ture vaccination policy for yellow fever vaccine. Published evidence does suggest that only 69% 
of children in Brazil maintained protective titres 10 years after receiving a full vaccine dose [85, 
92]. These articles however do not state the vaccine used which may be an important consider-
ation for the longevity of vaccine response. 
The sex, season of vaccination and time since vaccination did not impact the longevity of anti-
yellow fever antibody titre 5 - 6 years post vaccination in our study. This is similar to findings 
from antibody persistence studies 3 to 4 years post vaccination in a cohort of adult travellers 
vaccinated with yellow fever vaccine in the US. Early onset of viraemia and higher antibody titre 
one-month post vaccination were the only factors associated with higher antibody titres 3 to 4 
years post vaccination [95]. Such variables (onset of viraemia and antibody titres one-month 
post vaccination) were not available for our analysis. 
Conclusion 
There is an urgent need to consolidate the evidence around the potential need for booster vac-
cination with yellow fever vaccine following full and fractional doses in children and adults, and 
this priority has been identified by WHO [59, 62, 97]. This question is even more urgent to an-
swer as fractional doses are recommended in the face of outbreaks where there are yellow fe-
ver vaccine shortages [62]. 
Our findings would suggest that children in sub-Saharan Africa may require booster doses at 
least by school entry age. 
6.5 Future plans related to longevity of response to yellow fever 
Ultimately, samples will be sought from the regions with low versus high responders to compare 
long term responses and assess functionality more closely in studies designed to assess this 
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outcome. In addition, I aim to seek funding to conduct adequately powered sero surveys for yel-
low fever antibody titres from a cross section of the population to include school age children to 
further inform vaccination policy. This will hopefully form part of my post-doctoral studies. 
7. Correlating serum nutritional parameters to vaccine response (current findings inform-
ing future plans) 
7.1 Background and Rationale: 
Serum nutritional parameters with known immune modulating effects such as iron, vitamin D, 
may also modulate the response to vaccines. These effects of iron and vitamin D status are 
poorly studied in humans [98-100].   
Available data suggest the highest vitamin D deficiency is found in Asia, Africa and the Middle 
East [99]. Vitamin D is documented to influence innate and T cell immunity and shift balance to-
wards a Th1-type immune response [100]. There is also recent evidence to support a link be-
tween iron and vitamin D with a potential additive effect [99, 100].  
Maternal iron deficiency is well documented in low and middle-income countries (LMIC) and has 
been shown to affect new born iron status [98, 101, 102], Iron also influences innate immune 
responses, including the activation of NF-κB, a transcription factor, essential for the expression 
of several genes involved in innate immunity and inflammation [98, 102]. Nutritionally deprived 
mice have been shown to sequester iron from immune cells thus impairing immune function 
[102].  
For both iron and vitamin D, supplementation is potentially available, and improved understand-
ing of their impact on immunity in general and vaccine responses in particular could inform evi-
dence-based use of supplements for mothers or infants and/or use of currently available vac-
cines or aid new vaccine development. 
 
7.2 Methods: 
My work in the past 3 years has included co-leading a clinical study to characterize the ontog-
eny of molecular development in new born infants [103]. This involved a pilot study recruiting 30 
newborn infants between November and December 2015, within 24 hours of life from whom a 
blood sample was collected at this time point. A second sample was collected at day 1, 3 or 7 of 
life from 10 infants each [103]. Each 2ml sample was used to assess the transcriptome, metab-
olome and proteome of each newborn at 2 time points with the first week of life [103]. The find-
ings from the proteomic and transcriptomic portions of the analysis relate to this thesis. 
The proteomic assessment was done by mass spectrometry. The samples were grouped ac-
cording to the day of life, and proteins that were not quantifiable in at least five of the samples in 
any day were filtered out [103]. Proteins which showed statistically significant differences in 
abundance between the days of life were identified using a paired t test.  
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For the transcriptomic assessment, total ribonucleic acid (RNA) was extracted from the sample 
using the RiboPure RNA purification tool. Strand-specific cDNA libraries were generated from 
oly-adenylated RNA using the KAPA stranded RNA-Seq library preparation kit. All cDNA librar-
ies were generated from poly-adenylated RNA. Genes with very low counts and globin tran-
scripts were filtered out. Paired analysis with Wald statistic tests were used to identify differen-
tially expressed genes. A pairwise correlation of plasma concentrations of haemoglobin (Hb) 
subunits -alpha (HBA1), -beta (HBB), -gamma-1 (HBG1), and -gamma-2 (HBG2) was also per-
formed for each sample [103].  
 
7.3 Results: 
A portion of the results from this large multi-site effort relates to my PhD studies as presented 
below. 
A striking finding related to a nutritional marker, was the upregulation of scavenging heme – a 
product of erythrocyte breakdown, from plasma in addition to upregulation of the complement 
cascade which is also important for innate immune responses. This upregulation of heme scav-
enging may be similar to the phenomenon previously reported in nutritional deprived mice [102] 
and may also impair immune function in these infants. We also found that haemoglobin was 
abundant in the samples. The pairwise correlation of the different Hb subunits revealed that 
while the concentration of Hb was sample specific the ratio of the different haemoglobin subu-
nits was similar between the samples and conserved over the first week of life. These varying 
Hb concentrations may be correlated with maternal Hb and there is some evidence that mater-





Figure 7.1 Normalized abundance of haemoglobin subunits in newborn serum. 
Lee et al. Nature Coms https://doi.org/10.1038/s41467-019-08794-x 
 
The transcriptomic analysis also detected dramatic developmental changes when comparing 
day of life 0 to days 3 and 7. A number of pathways including cellular responses to stress, de-
toxification of reactive oxygen, and iron uptake and heme biosynthesis were down regulated. 
Other genes were up regulated including those involved in complement activation and interferon 
signaling [103]. 
 
7.4 Rationale for planned future analysis 
The upregulation of heme scavenging and Hb findings in this pilot study have sparked my inter-
est in understanding the potential impact of iron/heme regulation at the maternal/newborn inter-
face on subsequent responses to vaccines given at birth in the sub Saharan African context. In 
this context, deficiency of iron – a known immune modulator - is a major factor and the impact of 
the regulation of this known immune modulator on the response to vaccination during a period 
of documented iron deficiency and significant changes in iron regulation is key. Maternal iron 
deficiency is well documented in low and middle-income countries (LMIC) and has been shown 
to affect newborn iron status [98]. Iron also influences innate immune responses, including the 
activation of NF-κB, a transcription factor, essential for the expression of several genes involved 
in innate immunity and inflammation [102]. Nutritionally deprived mice have been shown to se-
quester needed iron from immune cells thus impairing immune function [102]. 
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I have identified vitamin D as an additional immune modulator whose impact on vaccine immu-
nogenicity is also under researched. Available data suggest the highest vitamin D deficiency is 
found in Asia, Africa and the Middle East. Vitamin D is documented to impair innate and T cell 
immunity and shift balance to a Th1 response [99, 100]. There is also recent evidence to sup-
port a link between iron and vitamin D which may result in an additive effect [105].  
 
7.5 Planned methodology for follow up: 
 
To test the hypothesis that these immune modulators may modulate the response to infant vac-
cines, I plan to correlate markers of serum iron (serum iron, C reactive protein, transferrin, solu-
ble transferrin receptor, ferritin, and hepcidin), and vitamin D metabolism (25(OH)D and 3-epi-
25(OH)D concentration) from mothers and infants to innate and vaccine induced immune re-
sponses. This will form part of my post-doctoral research and will be conducted within ongoing 
studies recruiting mother-infant pairs at the Medical Research Council Unit The Gambia at Lon-
don School of Hygiene and Tropical Medicine.  I will examine the relationship between maternal 
iron and vitamin D status and subsequent infant response to BCG and Hepatitis B vaccines, 
vaccines administered soon after birth in low- and middle-income countries (LMIC). I will also 
relate these vaccine responses to the infant iron and Vitamin D status and conduct additional 
exploratory proteomic analyses on infant samples to gain comprehensive insights. 
 
7.5.1 Research Questions 
1.  Does maternal iron status influence innate immune responses in newborns? 
2.  Does maternal iron status influence the immune response to BCG and Hepatitis B vaccines 
in newborns? 
3.  Can differences in infant immune responses be explained by the iron status of the mother 
and /or iron and vitamin D status of the infant or additional proteomic parameters? 
 
In ongoing studies, blood samples are being collected from women delivering at term at major 
health facilities in The Gambia and their infants at birth and following BCG and Hep B vaccina-
tion. Iron and vitamin D status will be measured in maternal samples; infant samples will be 
used to measure innate and vaccine-specific immune responses, the proteome, iron and vita-
min D status.  
Innate responses will be measured using cytokine and chemokine assays and TLR stimulation 
of whole blood; BCG responses will be measured using a flow-based cell mediated immunity 
(CMI) assay; Hepatitis B responses will be measured by IgG ELISA and CMI during the first 
week of life, and at ages 30 and 128 days. Iron status will be assessed using specific 
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iron indicators, inflammatory markers and hepcidin. Mass spectrometry will be used to quantify 
25 hydroxy vitamin D (25(OH)D) concentration and 3-epi-hydroxyvitamin D (3-epi-25(OH)D) - 
measures of vitamin D metabolism. 
 
8. Overall Conclusions: 
 
Seroconversion rates following yellow fever vaccination were significantly lower in Ghanaian 
compared to Malian infants. They were unaffected by season of vaccination, sex or nutritional 
status, although there was a trend to higher titres in males and in children with higher height for 
age z-scores, which is a measure of chronic malnutrition.  
There may be further need to systematically examine differences between the yellow fever vac-
cine strains contained in the variety of yellow fever vaccine preparations to guide best use of the 
available vaccines by decision makers. This is informed by the fact that receiving vaccines of 
varying compositions was the only major difference identified between these cohorts. 
Reassuringly, seroconversion rates to measles vaccine were not significantly impacted by an-
thropometric measures of malnutrition. Virtually all children in this cohort however had pre- vac-
cination IgG antibody concentrations below the definite threshold for protection implying that in-
fants at this age are vulnerable to infection possibly supporting the call for earlier measles vac-
cine doses. This factor is particularly key given the recent spate of measles outbreaks world-
wide. In addition, the observed sex differences (higher responses in females) would benefit from 
further studies to understand the factors mediating these differences and assess their clinical 
relevance- if any. Understanding the dynamics mediating these differences would help tailor im-
munization programmes to the population and could potentially inform future vaccine develop-
ment should precision vaccinology relating to vaccine doses for boys versus girls be consid-
ered. By 6 months post-vaccination, a small proportion no longer had protective immunity sup-
porting the need for booster measles vaccines. 
Anti-yellow fever antibody titres 5 – 6 years post vaccination were below protective thresholds in 
26.8 % of infants studied and completely undetectable in 21.8 %. This suggests an urgent need 
to consolidate the evidence around the potential need for booster vaccination with yellow fever 
vaccine following full and fractional doses in children and adults. This question is even more ur-
gent to answer as fractional doses are recommended in the face of outbreaks where there are 
yellow fever vaccine shortages. Our findings would suggest that children in sub-Saharan Africa 
may require booster doses at least by school entry age which is at variance with WHOs current 
policy of a single vaccine dose for life. 
Other nutritional factors such as iron status are known immune modulators and have been 
shown in our recent work to be down regulated in the immediate post delivery period. This may 
55 
have impact for responses to vaccines given during this period of rapid development after birth 



























1. Levels and Trends in Child Mortality United Nation 2017 report. 
https://www.unicef.org/publications/index_101071.html.   
2. Unicef, Under five mortailty. 2018 https://data.unicef.org/topic/child-survival/under-
five-mortality/. 
3. Levels and trends in child mortality. 2018 report https://www.un.org/en/develop-
ment/desa/population/publications/mortality/child-mortality-report-2018.asp. 
4. World Health Organization, Children: reducing mortality. 2018. 
5. Global Burden of Disease Collaborators, Estimates of global, regional, and 
national incidence, prevalence, and mortality of HIV, 1980-2015: the Global 
Burden of Disease Study 2015. Lancet HIV, 2016. 3(8): p. e361-e387. 
6. Jamison, D.T., et al., [Global health 2035: a world converging within a generation]. 
Salud Publica Mex, 2015. 57(5): p. 444-67. 
7. Tate, J.E., et al., Global, Regional, and National Estimates of Rotavirus Mortality 
in Children <5 Years of Age, 2000-2013. Clin Infect Dis, 2016. 62 Suppl 2: p. S96-
S105. 
8. Institute for Health Metrics and Evaluation (IHME), Findings from the Global 
Burden of Disease Study. 2018, IHME: Seattle, WA. 
9. Duclos, P., et al., Global immunization: status, progress, challenges and future. 
BMC Int Health Hum Rights, 2009. 9 Suppl 1: p. S2. 
10. Ozawa, S., et al., Estimated economic impact of vaccinations in 73 low- and 
middle-income countries, 2001-2020. Bull World Health Organ, 2017. 95(9): p. 
629-638. 
11. Idoko, O.T., et al., Impact, challenges, and future projections of vaccine trials in 
Africa. Am J Trop Med Hyg, 2013. 88(3): p. 414-9. 
12. Delany, I., R. Rappuoli, and E. De Gregorio, Vaccines for the 21st century. EMBO 
Mol Med, 2014. 6(6): p. 708-20. 
13. Okwo-Bele, J.M. and T. Cherian, The expanded programme on immunization: a 
lasting legacy of smallpox eradication. Vaccine, 2011. 29 Suppl 4: p. D74-9. 
14. Henderson, D.A., The eradication of smallpox--an overview of the past, present, 
and future. Vaccine, 2011. 29 Suppl 4: p. D7-9. 
15. Birn, A.E., Small(pox) success? Cien Saude Colet, 2011. 16(2): p. 591-7. 
16. Bagcchi, S., Polio endgame: overcoming the final barriers. Lancet Infect Dis, 2016. 
16(6): p. 644. 
17. Garon, J., et al., Polio endgame: the global switch from tOPV to bOPV. Expert Rev 
Vaccines, 2016. 15(6): p. 693-708. 
18. Patel, M., L. Menning, and P. Bhatnagar, Polio Eradication and Endgame Plan - 
Victory within Grasp. Indian Pediatr, 2016. 53 Suppl 1: p. S28-S32. 
19. Horzinek, M.C., Rinderpest: the second viral disease eradicated. Vet Microbiol, 
2011. 149(3-4): p. 295-7. 
20. Gutierrez Brito, M., et al., Immunogenicity and safety of 13-valent pneumococcal 
conjugate vaccine in Mexico. Rev Panam Salud Publica, 2013. 33(6): p. 414-21. 
21. Thompson, A., et al., Safety of 13-valent pneumococcal conjugate vaccine in 
infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine, 2013. 
31(45): p. 5289-95. 
22. Togashi, T., et al., Immunogenicity and safety of a 13-valent pneumococcal 
conjugate vaccine in healthy infants in Japan. Pediatr Infect Dis J, 2013. 32(9): p. 
984-9. 
57 
23. Zaman, K., et al., Effectiveness of a live oral human rotavirus vaccine after 
programmatic introduction in Bangladesh: A cluster-randomized trial. PLoS Med, 
2017. 14(4): p. e1002282. 
24. Naylor, C., et al., Environmental Enteropathy, Oral Vaccine Failure and Growth 
Faltering in Infants in Bangladesh. EBioMedicine, 2015. 2(11): p. 1759-66. 
25. UN Inter-agency Group for Child Mortality Estimation, Levels and Trends in Child 
Mortality. 2017. 
26. Black, R.E., et al., Maternal and child nutrition - Authors' reply. Lancet, 2013. 
382(9904): p. 1551-2. 
27. Rice, A.L., et al., Malnutrition as an underlying cause of childhood deaths 
associated with infectious diseases in developing countries. Bull World Health 
Organ, 2000. 78(10): p. 1207-21. 
28. Savy, M., et al., Landscape analysis of interactions between nutrition and vaccine 
responses in children. J Nutr, 2009. 139(11): p. 2154S-218S. 
29. Unicef, WHO, World Bank, Levels and trends in child malnutrition. 2017. 
30. Jones, K.D. and J.A. Berkley, Severe acute malnutrition and infection. Paediatr Int 
Child Health, 2014. 34 Suppl 1: p. S1-S29. 
31. Rytter, M.J., et al., The immune system in children with malnutrition--a systematic 
review. PLoS One, 2014. 9(8): p. e105017. 
32. Nicolini, L.A., et al., Insights on common vaccinations in HIV-infection: efficacy and 
safety. J Prev Med Hyg, 2015. 56(1): p. E28-32. 
33. Shafran, S.D., Live attenuated herpes zoster vaccine for HIV-infected adults. HIV 
Med, 2016. 17(4): p. 305-10. 
34. de Souza Campos Fernandes, R.C. and E. Medina-Acosta, BCG-itis in two 
antiretroviral-treated HIV-infected infants. Int J STD AIDS, 2010. 21(9): p. 662-3. 
35. Shrot, S., et al., BCGitis and BCGosis in children with primary immunodeficiency - 
imaging characteristics. Pediatr Radiol, 2016. 46(2): p. 237-45. 
36. Ishikawa, L.L., et al., Is the BCG vaccine safe for undernourished individuals? Clin 
Dev Immunol, 2012. 2012: p. 673186. 
37. WHO, Recommended routine immunizations for children. 2018. 
https://www.who.int/immunization/policy/immunization_tables/en/.  
38. Prentice, A.M., S.E. Moore, and A.J. Fulford, Growth faltering in low-income 
countries. World Rev Nutr Diet, 2013. 106: p. 90-9. 
39. Shrimpton, R., et al., Worldwide timing of growth faltering: implications for 
nutritional interventions. Pediatrics, 2001. 107(5): p. E75. 
40. Victora, C.G., et al., Worldwide timing of growth faltering: revisiting implications for 
interventions. Pediatrics, 2010. 125(3): p. e473-80. 
41. Project, M.V. Research and Development. Available from: 
http://www.meningvax.org/researchdevelopment.html. 
42. World Health, O. Child growth standards. 2007; Available from: 
http://www.who.int/childgrowth/standards/weight_for_age/en/. 
43. Schoeps, A., et al., No effect of an additional early dose of measles vaccine on 
hospitalization or mortality in children: A randomized controlled trial. Vaccine, 2018. 
36(15): p. 1965-1971. 
44. Collaborative Group for Studies of Yellow Fever, V., A randomised double-blind 
clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-
213/77 in children nine-23 months old. Mem Inst Oswaldo Cruz, 2015. 110(6): p. 
771-80. 
45. Collaborative group for studies on yellow fever, v., Duration of post-vaccination 
immunity against yellow fever in adults. Vaccine, 2014. 32(39): p. 4977-84. 
58 
46. Klein, S.L. and K.L. Flanagan, Sex differences in immune responses. Nat Rev 
Immunol, 2016. 16(10): p. 626-38. 
47. Klein, S.L., I. Marriott, and E.N. Fish, Sex-based differences in immune function 
and responses to vaccination. Trans R Soc Trop Med Hyg, 2015. 109(1): p. 9-15. 
48. Nascimento Silva, J.R., et al., Mutual interference on the immune response to 
yellow fever vaccine and a combined vaccine against measles, mumps and rubella. 
Vaccine, 2011. 29(37): p. 6327-34. 
49. Clarke, E., et al., Safety and immunogenicity of inactivated poliovirus vaccine when 
given with measles-rubella combined vaccine and yellow fever vaccine and when 
given via different administration routes: a phase 4, randomised, non-inferiority trial 
in The Gambia. Lancet Glob Health, 2016. 4(8): p. e534-47. 
50. Moore, S.E., et al., Effect of month of vaccine administration on antibody 
responses in The Gambia and Pakistan. Trop Med Int Health, 2006. 11(10): p. 
1529-41. 
51. Idoko, O.T., et al., The impact of pre-existing antibody on subsequent immune 
responses to meningococcal A-containing vaccines. Vaccine, 2014. 32(33): p. 
4220-7. 
52. Staples, J.E. and T.P. Monath, Yellow fever: 100 years of discovery. JAMA, 2008. 
300(8): p. 960-2. 
53. SAGE Working Group, Background Paper on Yellow Fever Vaccine. 2013. 
54. Blake, L.E. and M.A. Garcia-Blanco, Human genetic variation and yellow fever 
mortality during 19th century U.S. epidemics. MBio, 2014. 5(3): p. e01253-14. 
55. Barrett, A.D.T., Yellow fever live attenuated vaccine: A very successful live 
attenuated vaccine but still we have problems controlling the disease. Vaccine, 
2017. 35(44): p. 5951-5955. 
56. Kollmann, T.R. and A. Marchant, Towards Predicting Protective Vaccine 
Responses in the Very Young. Trends Immunol, 2016. 37(8): p. 523-534. 
57. Roy Chowdhury, P., et al., Immunogenicity of Yellow Fever Vaccine 
Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali. Clin Infect 
Dis, 2015. 61 Suppl 5: p. S586-93. 
58. Vaccines and vaccination against yellow fever. WHO position paper -- June 2013. 
Wkly Epidemiol Rec, 2013. 88(27): p. 269-83. 
59. WHO, Vaccines and vaccination against yellow fever: WHO Position Paper, June 
2013--recommendations. Vaccine, 2015. 33(1): p. 76-7. 
60. Yellow fever vaccine: WHO position on the use of fractional doses - June 2017. 
Wkly Epidemiol Rec, 2017. 92(25): p. 345-50. 
61. World Health Organization, Yellow fever vaccine. WHO position paper. Wkly 
Epidemiol Rec, 2003. 78(40): p. 349-59. 
62. World Health Organization, WHO position on the use of fractional doses - June 
2017, addendum to vaccines and vaccination against yellow fever WHO: Position 
paper - June 2013. Vaccine, 2017. 35(43): p. 5751-5752. 
63. Griffin, D.E., Measles Vaccine. Viral Immunol, 2018. 31(2): p. 86-95. 
64. Moss, W.J. and D.E. Griffin, Measles. Lancet, 2012. 379(9811): p. 153-64. 
65. WHO, Measles cases spike globally due to gaps in vaccination coverage. 2019. 
66. European Centre for Disease Prevention and Control, Monthly measles and 
rubella monitoring report, March 2019. 2019. 
67. World Health Organization, Measles and Rubella Surveillance data. 2019. 
68. WHO, Measles - Madagascar, in Emergency preparedness, response. 2019. 
69. WHO, Progress toward regional measles elimination - worldwide 2000 - 2017. 
2018. 
59 
70. Maughan, E.D. and D. Davis, The Measles Outbreak: School Nurses' Population-
based Care Super Power. NASN Sch Nurse, 2019. 34(3): p. 179-183. 
71. Plotkin, S.A., Correlates of protection induced by vaccination. Clin Vaccine 
Immunol, 2010. 17(7): p. 1055-65. 
72. Kizito, D., et al., Factors affecting the infant antibody response to measles 
immunisation in Entebbe-Uganda. BMC Public Health, 2013. 13: p. 619. 
73. WHO, Results from MenA vaccine randomized controlled trials in infants and 
young children – Executive summary for SAGE. 
74. Singh, J., International conference on harmonization of technical requirements for 
registration of pharmaceuticals for human use. J Pharmacol Pharmacother, 2015. 
6(3): p. 185-7. 
75. Dixon, J.R., Jr., The International Conference on Harmonization Good Clinical 
Practice guideline. Qual Assur, 1998. 6(2): p. 65-74. 
76. Mason, R.A., et al., Yellow fever vaccine: direct challenge of monkeys given 
graded doses of 17D vaccine. Appl Microbiol, 1973. 25(4): p. 539-44. 
77. StataCorp, Stata Statistical Software: Release 14. College Station, TX: StataCorp 
LP. 2015. 
78. Ratnam, S., et al., Comparison of commercial enzyme immunoassay kits with 
plaque reduction neutralization test for detection of measles virus antibody. J Clin 
Microbiol, 1995. 33(4): p. 811-5. 
79. Chen, R.T., et al., Measles antibody: reevaluation of protective titers. J Infect Dis, 
1990. 162(5): p. 1036-42. 
80. Samb, B., et al., Serologic status and measles attack rates among vaccinated and 
unvaccinated children in rural Senegal. Pediatr Infect Dis J, 1995. 14(3): p. 203-9. 
81. dos Santos, C.N., et al., Complete nucleotide sequence of yellow fever virus 
vaccine strains 17DD and 17D-213. Virus Res, 1995. 35(1): p. 35-41. 
82. Martins, R.M., et al., 17DD yellow fever vaccine: a double blind, randomized 
clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin 
Immunother, 2013. 9(4): p. 879-88. 
83. Pfister, M., et al., Immunogenicity and safety of BERNA-YF compared with two 
other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg, 
2005. 72(3): p. 339-46. 
84. Izurieta, R.O., et al., Anamnestic immune response to dengue and decreased 
severity of yellow Fever. J Glob Infect Dis, 2009. 1(2): p. 111-6. 
85. Plotkin, S.A., Ten yearly yellow fever booster vaccinations may still be justified. J 
Travel Med, 2018. 25(1). 
86. Guerra, F.M., et al., Waning of measles maternal antibody in infants in measles 
elimination settings - A systematic literature review. Vaccine, 2018. 36(10): p. 
1248-1255. 
87. Fisker, A.B., et al., A Two-Center Randomized Trial of an Additional Early Dose of 
Measles Vaccine: Effects on Mortality and Measles Antibody Levels. Clin Infect 
Dis, 2018. 66(10): p. 1573-1580. 
88. Martins, C., et al., Girls may have lower levels of maternal measles antibodies and 
higher risk of subclinical measles infection before the age of measles vaccination. 
Vaccine, 2009. 27(38): p. 5220-5. 
89. Dominguez, A., et al., Seroprevalence of measles, rubella, and mumps antibodies 
in Catalonia, Spain: results of a cross-sectional study. Eur J Clin Microbiol Infect 
Dis, 2006. 25(5): p. 310-7. 
90. Knudsen, K.M., et al., Child mortality following standard, medium or high titre 
measles immunization in West Africa. Int J Epidemiol, 1996. 25(3): p. 665-73. 
60 
91. DiazGranados, C.A., et al., Efficacy of high-dose versus standard-dose influenza 
vaccine in older adults. N Engl J Med, 2014. 371(7): p. 635-45. 
92. de Melo, A.B., et al., Description of a prospective 17DD yellow fever vaccine cohort 
in Recife, Brazil. Am J Trop Med Hyg, 2011. 85(4): p. 739-47. 
93. Roukens, A.H.E., et al., Long-Term Protection After Fractional-Dose Yellow Fever 
Vaccination: Follow-up Study of a Randomized, Controlled, Noninferiority Trial. 
Ann Intern Med, 2018. 169(11): p. 761-765. 
94. Lindsey, N.P., et al., Persistence of yellow fever virus-specific neutralizing 
antibodies after vaccination among US travellers. J Travel Med, 2018. 25(1). 
95. Gibney, K.B., et al., Detection of anti-yellow fever virus immunoglobulin m 
antibodies at 3-4 years following yellow fever vaccination. Am J Trop Med Hyg, 
2012. 87(6): p. 1112-5. 
96. Sow, S.O., et al., Immunogenicity and safety of a meningococcal A conjugate 
vaccine in Africans. N Engl J Med, 2011. 364(24): p. 2293-304. 
97. Vannice, K.S., et al., Active Surveillance for Adverse Events After a Mass 
Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-
TT) in Mali. Clin Infect Dis, 2015. 61 Suppl 5: p. S493-500. 
98. Coe, C.L., G.R. Lubach, and E.A. Shirtcliff, Maternal stress during pregnancy 
predisposes for iron deficiency in infant monkeys impacting innate immunity. 
Pediatr Res, 2007. 61(5 Pt 1): p. 520-4. 
99. Roth, D.E., et al., Global prevalence and disease burden of vitamin D deficiency: 
a roadmap for action in low- and middle-income countries. Ann N Y Acad Sci, 2018. 
1430(1): p. 44-79. 
100. O'Callaghan, K.M., et al., Estimation of the maternal vitamin D intake that 
maintains circulating 25-hydroxyvitamin D in late gestation at a concentration 
sufficient to keep umbilical cord sera >/=25-30 nmol/L: a dose-response, double-
blind, randomized placebo-controlled trial in pregnant women at northern latitude. 
Am J Clin Nutr, 2018. 108(1): p. 77-91. 
101. Shero, N., et al., Impact of maternal iron deficiency on the auditory functions in the 
young and adult guinea pig. Nutr Neurosci, 2017: p. 1-9. 
102. Jabara, H.H., et al., A missense mutation in TFRC, encoding transferrin receptor 
1, causes combined immunodeficiency. Nat Genet, 2016. 48(1): p. 74-8. 
103. Lee, A.H., et al., Dynamic molecular changes during the first week of human life 
follow a robust developmental trajectory. Nat Commun, 2019. 10(1): p. 1092. 
104. Terefe, B., et al., Effect of maternal iron deficiency anemia on the iron store of 
newborns in ethiopia. Anemia, 2015. 2015: p. 808204. 
105. Mann E.H., Vitamin D and Adaptive Immunology in Health and Disease. Vitamin 












Statement on Pre-release and Contribution 
The analysis of the relationship between yellow fever vaccination titres and anthropom-
etry has been accepted for publication in ‘Expert Review of Vaccines’. This manuscript 
was written by the PhD candidate. The analysis was designed and conducted by the 
candidate with support from Prof Beate Kampmann and Dr Elmar Saathoff. 
The portion on iron status of the newborn has been published (see Nature Communica-
tions manuscript below) and further analysis will be the basis of future work. 
Other portions of the thesis on measles vaccine responses and the longevity of the re-
sponse to yellow fever vaccine are currently being prepared for submission for peer re-
view and subsequent publication. 
Manuscripts attached to monographic thesis:  
See section 1, 2, 3, 4and 5 of thesis 
1. Idoko OT, Mohammed N, Ansah P, Hodgson A, Tapia M, Sow S, Chowdhury 
PR, Niedrig M, Saathoff E, Kampmann B, Antibody responses to yellow fever 
vaccine in 9 – 11-month-old Malian and Ghanaian children. Expert Review of 
Vaccines. 2019 doi.org/10.1080/14760584.2019.1640118. 
 
Candidates Contribution: 
This manuscript outlines the IgG responses to yellow fever vaccines measured by sero 
neutralization assay in 9 to 11-month-old (at time of vaccination) African infants from 
Ghana and Mali. Neutralizing antibodies following vaccination were unaffected by sea-
son of vaccination, sex, pre vaccination titres or nutritional status measured by anthro-
pometry. There was however a trend for higher titres in males and children with higher z 
scores for age (a measure of chronic malnutrition). The seroconversion rates differed 
significantly between the 2 countries studied suggesting a possible need for booster 
vaccinations. 
The candidate designed and conducted the analysis for this manuscript and wrote the 
manuscript. 
See section 8 of thesis 
2. Lee AH*, Shannon CP*, Amenyogbe N*, Bennike TB*, Diary-Arce J*, Idoko OT*, 
Gill EE, Ben-Othman R, Pomat WS, van Haren SD, le Cao KA, Cox M, Darboe 
A, Falsafi R, Ferrari D, Harbeson DJ, He D, Bing C, Hinshaw SJ, Ndure J, Njie-
62 
Jobe J, Pettengill MA, Richmond PC, Ford R, Saleu G, Masiria G, Matlam JP, 
Kirarock W, Roberts E, Malek M, Sanchez-Schimtz G, Singh A, Angelidou A, 
Smolen K, The EPIC Consortium, Brinkman RR, Ozonoff A, Hancock REW, van 
den Biggelaar AHJ, Steen H, Tebbutt SJ, Kampmann B, Levy O, Kollmann TR, 
Dynamic molecular changes during the first week of human life follow a robust developmental 
trajectory. Nature Communications. 2019; DOI:10.1038/s41467-019-08794-x. 
NB: * Joint co first authors  
 
Candidates contribution: 
This manuscript outlines changes at a molecular level to a newborn within the first 7 
days of life a period crucial for immune development which ultimately impacts the re-
sponse to vaccines. Using multi omic techniques the data reveal a dynamic purposeful 
molecular trajectory of development over the first week of life. Of note we demonstrated 
upregulation of home scavenging during the first week of life. There is evidence to sug-
gest that this may be an attempt to protect the infant from infection by making iron less 
available for microorganisms (an immune defence mechanism). Given the prevalence of 
iron deficiency in sub-Saharan Africa where I live and work, especially during the crucial 
period of pregnancy, I intend to take this finding into future studies to explore the impact 
of iron markers and metabolism on the innate and vaccine responses at the maternal- 
newborn interphase. Details of this are given in Section 8 of the thesis. 
I designed the clinical protocols and documents used to undertake the study and re-
cruited all 30 newborn infants whose data and samples were assessed. I also provided 
clinical oversight and wrote the clinical methods section of the manuscript. I contributed 
to data interpretation and reviewed the full manuscript. 
 
Acknowledgments 
My gratitude goes to: 
a. My supervisory team Prof Beate Kampmann, Dr Elmar Saathoff and Dr Christof 
Geldmacher for their invaluable support and guidance. I have grown immensely 
through this process. 
Thank you Beate for creating an enabling environment, the many meetings, the 
endless refining and the friendship and mentorship. 
Thank you Elmar for each critical review and the many calls. 
Thank you, Christof, for your reviews and input and encouragement. 
63 
b. The Meningitis Vaccine Project, Program for Appropriate Technology in Health Se-
rum Institute India, for the data and serum that contributed to this analysis and for 
reviewing my proposal to use this data and samples. 
c. Participants and co investigators from previous trials whose samples and data I 
was able to access. 
d. Dr Carla Cerami and Andrew Prentice for advice on assessment of iron status and 
Dr Nicholas Grassly for discussing current knowledge in the field of anthropometry 
and vaccine responses during the early days of my PhD. To Nuredin Ibrahim for 
statistical advice and support. 
e. Dr Christina Domingo Carrasco of Robert Koch Institute for leading the assays of 
yellow fever antibody for the longevity of antibody response and Patrick Okot for 
supervising the iron assays. 
f. Wellcome Trust Institutional Strategic Support Fund through Imperial College Lon-
don for funding.  
g. Friends, family and colleagues too numerous to mention for all your words of en-
couragement and guidance. 
h. My long-suffering husband Dr Patrick Idoko, and children Ehicocho, Edoka and 
Ejembi for giving up time with me and providing a conducive environment to allow 
me to undertake this PhD. For your words of encouragement, prayers, the times 
you wiped my tears and the times you gave me the needed distraction from wading 
through the data. My mother Mrs Florence Adebola Anjorin for dropping everything 
to babysit time and again, offering a nudge every now and then and constantly 
being on her knees. Elizabeth and Patrick carried a fair share of the household 
duties. These precious ones have made the task of juggling so much lighter. Clem-
ent and Virginia Idoko have been pillars of support. Through my career I increas-
ingly find that quality time with family is a much-needed stimulus to keep my tasks 
outside the home going. 
i. My father of blessed memory Prof Felix Idowu Anjorin who always encouraged me 
to reach for the stars. My first mentor, my teacher, my friend, my confidant… I’m 
still at it Daddy…. 
j. And my Lord and God in whom all things hold together. 
